WO2023169327A1 - 一种哒嗪类衍生物的晶型、制备方法及其应用 - Google Patents

一种哒嗪类衍生物的晶型、制备方法及其应用 Download PDF

Info

Publication number
WO2023169327A1
WO2023169327A1 PCT/CN2023/079559 CN2023079559W WO2023169327A1 WO 2023169327 A1 WO2023169327 A1 WO 2023169327A1 CN 2023079559 W CN2023079559 W CN 2023079559W WO 2023169327 A1 WO2023169327 A1 WO 2023169327A1
Authority
WO
WIPO (PCT)
Prior art keywords
crystal form
ray powder
powder diffraction
diffraction spectrum
characteristic peaks
Prior art date
Application number
PCT/CN2023/079559
Other languages
English (en)
French (fr)
Inventor
吴颢
陈亮
杨晓峰
徐斌
杜亚军
王维
敖桔
王家炳
兰宏
丁列明
Original Assignee
贝达药业股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 贝达药业股份有限公司 filed Critical 贝达药业股份有限公司
Publication of WO2023169327A1 publication Critical patent/WO2023169327A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the invention relates to a pyridazine derivative 5-(6-chloro-5-((1S,2S)-2-phenylcyclopropyl)pyridazin-3-yl)pyrimidine-2,4(1H,3H )-Crystal form, preparation method and application of diketone.
  • Extracellular 5'-nucleotidase is a glycoprotein on the cell membrane that exists on the cell membrane surface of various cell types, including endothelial cells, lymphocytes, stromal cells and tumor cells. wait. CD73 can catalyze extracellular 5'-adenosine monophosphate (5'-AMP) to generate adenosine, which can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. In addition, CD73 can also promote tumorigenesis through non-immune-related mechanisms, such as promoting tumor angiogenesis and promoting the adhesion of tumor cells to extracellular matrix proteins. Clinically, high-level expression of CD73 is associated with lymph node metastasis and poor prognosis in multiple cancer types, and CD73 has been found to be an independent prognostic factor in patients with prostate cancer and triple-negative breast cancer.
  • 5'-AMP extracellular 5'-adenosine monophosphate
  • CD73 can also promote tumorigenesis through non-immune-related mechanisms, such as
  • the present invention provides a pyridazine derivative 5-(6-chloro-5-((1S,2S)-2-phenylcyclopropyl)pyridazin-3-yl)pyrimidine-2,4( The crystal form, preparation method and application of 1H, 3H)-diketone (compound (I)) free base.
  • the invention provides a pyridazine derivative 5-(6-chloro-5-((1S,2S)-2-phenylcyclopropyl)pyridazin-3-yl)pyrimidine-2,4(1H,3H )-diketone (compound (I)) free base crystal form A.
  • the crystal form A of the compound represented by formula (I) is characterized in that the X-ray powder diffraction spectrum has characteristics at 2 ⁇ of 4.521°, 7.268°, 11.930°, 15.837° and 16.946°. Peak, 2 ⁇ value error range is ⁇ 0.2°.
  • the crystal form A of the compound represented by formula (I) is characterized in that the X-ray powder diffraction spectrum at 2 ⁇ is 4.521°, 7.268°, 11.442°, 11.930°, 15.837°, 16.946° There are characteristic peaks at and 22.717°, and the 2 ⁇ value error range is ⁇ 0.2°.
  • the crystal form A of the compound represented by formula (I) is characterized in that the X-ray powder diffraction spectrum at 2 ⁇ is 4.521°, 7.268°, 11.442°, 11.930°, 15.141°, 15.518° There are characteristic peaks at , 15.837°, 16.946°, 22.717°, 23.867° and 25.581°, and the 2 ⁇ value error range is ⁇ 0.2°.
  • the crystal form A of the compound represented by formula (I) is characterized in that the X-ray powder diffraction spectrum has the characteristic peaks shown in Figure 1.
  • the crystal form A of the compound represented by formula (I) is characterized in that the mDSC curve of the crystal form has an endothermic peak at 258.0°C ⁇ 3°C.
  • the mDSC curve spectrum As shown in 2.
  • the preparation method of crystal form A of the compound represented by formula (I) includes: adding compound (I) to an acetone solution, raising the temperature to 50°C, stirring, suction filtration and drying steps. .
  • the invention provides a pyridazine derivative 5-(6-chloro-5-((1S,2S)-2-phenylcyclopropyl)pyridazin-3-yl)pyrimidine-2,4(1H,3H )-diketone (compound (I)) free base crystal form B.
  • the crystal form B of the compound represented by formula (I) is characterized in that the X-ray powder diffraction spectrum has characteristic peaks at 2 ⁇ of 4.789°, 15.673° and 24.161°, and the 2 ⁇ value error range is is ⁇ 0.2°.
  • the crystal form B of the compound represented by formula (I) is characterized in that the X-ray powder diffraction spectrum has characteristic peaks at 2 ⁇ of 4.789°, 9.598°, 15.673° and 24.161°, 2 ⁇
  • the value error range is ⁇ 0.2°.
  • the crystal form B of the compound represented by formula (I) is characterized in that the X-ray powder diffraction spectrum has characteristics at 2 ⁇ of 4.789°, 9.598°, 14.424°, 15.673° and 24.161°. Peak, 2 ⁇ value error range is ⁇ 0.2°.
  • the crystalline form B of the compound represented by formula (I) is characterized in that the X-ray powder diffraction spectrum at 2 ⁇ is 4.789°, 9.598°, 10.076°, 14.424°, 15.275°, 15.673° There are characteristic peaks at , 19.262° and 24.161°, and the 2 ⁇ value error range is ⁇ 0.2°.
  • the crystalline form B of the compound represented by formula (I) is characterized in that the X-ray powder diffraction spectrum at 2 ⁇ is 4.789°, 9.598°, 10.076°, 14.424°, 15.275°, 15.673° There are characteristic peaks at , 19.262°, 19.714°, 19.989°, 20.229°, 24.161° and 27.193°, and the 2 ⁇ value error range is ⁇ 0.2°.
  • the crystal form B of the compound represented by formula (I) is characterized in that the X-ray powder diffraction spectrum has the characteristic peaks shown in Figure 4.
  • the crystal form B of the compound represented by formula (I) is characterized in that the mDSC curve of the crystal form B has an endothermic peak at 228.7°C ⁇ 3°C and 244.9°C ⁇ 3°C, There is an exothermic peak at 245.2°C ⁇ 3°C.
  • its DSC curve is as shown in 5.
  • the preparation method of crystal form B of the compound represented by formula (I) includes: adding compound (I) to an acetone solution, raising the temperature to 25°C, stirring, suction filtration and drying steps. .
  • the preparation method of crystal form B of the compound represented by formula (I) includes: adding compound (I) to the ethanol solution, raising the temperature to 25°C, stirring, suction filtration and drying steps. .
  • the invention provides a pyridazine derivative 5-(6-chloro-5-((1S,2S)-2-phenylcyclopropyl)pyridazin-3-yl)pyrimidine-2,4(1H,3H )-diketone (compound (I)) free base crystal form C.
  • the crystal form C of the compound represented by formula (I) is characterized in that the X-ray powder diffraction spectrum at 2 ⁇ is 3.854°, 5.250°, 7.126°, 14.870°, 16.357°, 19.629° There are characteristic peaks at , 21.613°, and 21.982°, and the 2 ⁇ value error range is ⁇ 0.2°.
  • the crystal form C of the compound represented by formula (I) is characterized in that the X-ray powder diffraction spectrum at 2 ⁇ is 3.854°, 5.250°, 7.126°, 14.870°, 15.925°, 16.357° There are characteristic peaks at , 18.581°, 19.629°, 21.613° and 21.982°, and the 2 ⁇ value error range is ⁇ 0.2°.
  • the crystal form C of the compound represented by formula (I) is characterized in that the X-ray powder diffraction spectrum at 2 ⁇ is 3.854°, 5.250°, 7.126°, 14.870°, 15.925°, 16.357° There are characteristic peaks at , 18.581°, 19.629°, 21.613°, 21.982°, 23.831°, 25.578°, 30.069°, 33.684° and 36.482°, and the 2 ⁇ value error range is ⁇ 0.2°.
  • the crystal form C of the compound represented by formula (I) is characterized in that the X-ray powder diffraction spectrum has the characteristic peaks shown in Figure 7.
  • the crystalline form C of the compound represented by formula (I) is characterized in that the DSC curve of the crystalline form C has an exothermic peak at 268.1°C ⁇ 3°C.
  • the DSC curve of the crystalline form C has an exothermic peak at 268.1°C ⁇ 3°C.
  • its DSC curve The graph is shown in 8.
  • the preparation method of crystal form C of the compound represented by formula (I) includes: adding compound (I) to a mixed solution of tetrahydrofuran/water, raising the temperature to 50°C, stirring, and cooling. , suction filtration, collect the filtrate, add n-heptane to the filtrate, and lower the temperature again and suction filtration step.
  • the volume ratio of the tetrahydrofuran to water is 14:1.
  • the invention provides a pyridazine derivative 5-(6-chloro-5-((1S,2S)-2-phenylcyclopropyl)pyridazin-3-yl)pyrimidine-2,4(1H,3H )-diketone (compound (I)) free base crystal form D.
  • the crystalline form D of the compound represented by formula (I) is characterized in that the X-ray powder diffraction spectrum at 2 ⁇ is 4.661°, 12.132°, 15.653°, 23.500°, 26.514° and 27.356°. There is a characteristic peak at , and the 2 ⁇ value error range is ⁇ 0.2°.
  • the crystal form D of the compound represented by formula (I) is characterized in that the X-ray powder diffraction spectrum at 2 ⁇ is 4.661°, 12.132°, 14.033°, 15.653°, 17.891°, 19.937° There are characteristic peaks at , 23.500°, 24.942°, 26.514° and 27.356°, and the 2 ⁇ value error range is ⁇ 0.2°.
  • the crystal form D of the compound represented by formula (I) is characterized in that the X-ray powder diffraction spectrum has the characteristic peaks shown in Figure 10.
  • the crystalline form D of the compound represented by formula (I) is characterized in that the DSC curve of the crystalline form D has an exothermic peak at 274.5°C ⁇ 3°C.
  • the DSC curve of the crystalline form D has an exothermic peak at 274.5°C ⁇ 3°C.
  • its DSC curve The graph is shown in 11.
  • the preparation method of crystal form D of the compound represented by formula (I) includes: adding compound (I) to a dichloromethane solution, raising the temperature to 50°C, stirring, suction filtration and Drying step.
  • the invention provides a pyridazine derivative 5-(6-chloro-5-((1S,2S)-2-phenylcyclopropyl)pyridazin-3-yl)pyrimidine-2,4(1H,3H )-diketone (compound (I)) free base crystal form F.
  • the crystal form F of the compound represented by formula (I) is characterized in that the X-ray powder diffraction spectrum at 2 ⁇ is 4.525°, 6.885°, 11.848°, 14.337°, 16.594° and 24.492° There is a characteristic peak at , and the 2 ⁇ value error range is ⁇ 0.2°.
  • the crystal form F of the compound represented by formula (I) is characterized in that the X-ray powder diffraction spectrum at 2 ⁇ is 4.525°, 6.885°, 11.021°, 11.848°, 14.337°, 16.594° There are characteristic peaks at , 22.965° and 24.492°, and the 2 ⁇ value error range is ⁇ 0.2°.
  • the crystal form F of the compound represented by formula (I) is characterized in that the X-ray powder diffraction spectrum at 2 ⁇ is 4.525°, 5.471°, 6.885°, 9.492°, 11.021°, 11.848° There are characteristic peaks at , 13.311°, 14.337°, 14.893°, 16.594°, 17.182°, 18.276°, 22.965°, 24.492° and 25.446°, and the 2 ⁇ value error range is ⁇ 0.2°.
  • the crystal form F of the compound represented by formula (I) is characterized in that the X-ray powder diffraction spectrum has the characteristic peaks shown in Figure 13.
  • the crystal form F of the compound represented by formula (I) is characterized in that the DSC curve of the crystal form F has an endothermic peak at 47.6°C ⁇ 3°C and an endothermic peak at 276.9°C ⁇ 3°C. There is an exothermic peak at , preferably, its DSC curve is shown in 14.
  • the preparation method of crystal form F of the compound represented by formula (I) includes: adding compound (I) to the methanol solution, raising the temperature to 50°C, stirring, suction filtration and drying steps .
  • the invention provides a pyridazine derivative 5-(6-chloro-5-((1S,2S)-2-phenylcyclopropyl)pyridazin-3-yl)pyrimidine-2,4(1H,3H )-diketone (compound (I) free base crystal form G.
  • the crystal form G of the compound represented by formula (I) is characterized in that the X-ray powder diffraction spectrum at 2 ⁇ is 5.986°, 6.956°, 14.011°, 17.552°, 19.157° and 24.343°. There is a characteristic peak at , and the 2 ⁇ value error range is ⁇ 0.2°.
  • the crystal form G of the compound represented by formula (I) is characterized in that the X-ray powder diffraction spectrum at 2 ⁇ is 5.986°, 6.956°, 14.011°, 17.552°, 19.157°, 22.300° There are characteristic peaks at , 23.443° and 24.343°, and the 2 ⁇ value error range is ⁇ 0.2°.
  • the crystalline form G of the compound represented by formula (I) is characterized in that the X-ray powder diffraction spectrum at 2 ⁇ is 5.986°, 6.956°, 14.011°, 14.354°, 17.552°, 18.195° There are characteristic peaks at , 19.157°, 19.509°, 19.922°, 22.300°, 23.443°, 24.343°, 25.928°, 29.391° and 30.476°, and the 2 ⁇ value error range is ⁇ 0.2°.
  • the crystal form G of the compound represented by formula (I) is characterized in that the X-ray powder diffraction spectrum has the characteristic peaks shown in Figure 16.
  • the crystalline form G of the compound represented by formula (I) is characterized in that the DSC curve of the crystalline form G is at 110.1°C ⁇ 3°C, 128.0°C ⁇ 3°C and 141.8°C ⁇ 3°C. There is an endothermic peak and an exothermic peak at 251.4°C ⁇ 3°C. Preferably, its DSC curve is as shown in 17.
  • the preparation method of crystal form G of the compound represented by formula (I) includes: adding compound (I) to a mixed solution of dimethyl sulfoxide/butanone, and raising the temperature to 50 °C, stirring, suction filtration and drying steps.
  • the volume ratio of dimethyl sulfoxide: butanone in the mixed solution of dimethyl sulfoxide/butanone is 1: 1.
  • the invention provides a pyridazine derivative 5-(6-chloro-5-((1S,2S)-2-phenylcyclopropyl)pyridazin-3-yl)pyrimidine-2,4(1H,3H )-diketone (compound (I)) free base crystal form H.
  • the crystal form H of the compound represented by formula (I) is characterized by having characteristic peaks at 2 ⁇ of 11.838°, 16.771°, 21.451° and 22.524° in the X-ray powder diffraction spectrum, 2 ⁇
  • the value error range is ⁇ 0.2°.
  • the crystal form H of the compound represented by formula (I) is characterized in that the X-ray powder diffraction spectrum at 2 ⁇ is 11.838°, 16.771°, 17.251°, 21.451°, 22.524°, 23.494° There are characteristic peaks at and 26.982°, and the 2 ⁇ value error range is ⁇ 0.2°.
  • the crystal form H of the compound represented by formula (I) is characterized in that the X-ray powder diffraction spectrum at 2 ⁇ is 9.087°, 9.518°, 10.650°, 11.838°, 12.105°, 16.771° ,17.251°,19.655°,19.831°, There are characteristic peaks at 20.328°, 21.451°, 22.524°, 23.494°, 24.783°, 26.982° and 27.507°, and the 2 ⁇ value error range is ⁇ 0.2°.
  • the crystal form H of the compound represented by formula (I) is characterized in that the X-ray powder diffraction spectrum has the characteristic peaks shown in Figure 19.
  • the crystalline form H of the compound represented by formula (I) is characterized in that the DSC curve of the crystalline form H is at 95.8°C ⁇ 3°C, 107.2°C ⁇ 3°C and 117.8°C ⁇ 3°C. There is an endothermic peak and an exothermic peak at 263.1°C ⁇ 3°C. Preferably, its DSC curve is as shown in 20.
  • the preparation method of crystal form H of the compound represented by formula (I) includes: adding compound (I) to a mixed solution of dimethyl sulfoxide/ethyl acetate, and heating to 50°C, stirring, suction filtration and drying steps.
  • the preparation method of crystal form G of the compound represented by formula (I), the volume ratio of dimethyl sulfoxide: butanone in the mixed solution of dimethyl sulfoxide/ethyl acetate is 1 :9.
  • the invention provides a pyridazine derivative 5-(6-chloro-5-((1S,2S)-2-phenylcyclopropyl)pyridazin-3-yl)pyrimidine-2,4(1H,3H )-diketone (compound (I)) free base crystal form I.
  • the crystal form I of the compound represented by formula (I) is characterized in that the X-ray powder diffraction spectrum has characteristic peaks at 2 ⁇ of 3.999°, 6.693°, 13.476° and 20.308°, 2 ⁇ The value error range is ⁇ 0.2°.
  • the crystal form I of the compound represented by formula (I) is characterized in that the X-ray powder diffraction spectrum in the 2 ⁇ is 3.999°, 5.042°, 6.693°, 13.476°, 20.308°, 26.507° There are characteristic peaks at and 27.212°, and the 2 ⁇ value error range is ⁇ 0.2°.
  • the crystal form I of the compound represented by formula (I) is characterized in that the X-ray powder diffraction spectrum at 2 ⁇ is 3.999°, 5.042°, 6.693°, 13.476°, 16.656°, 20.308° There are characteristic peaks at , 22.481°, 23.476°, 26.507°, 27.212°, 27.852°, 28.944° and 34.216°, and the 2 ⁇ value error range is ⁇ 0.2°.
  • the crystal form I of the compound represented by formula (I) is characterized in that the X-ray powder diffraction spectrum has the characteristic peaks shown in Figure 22.
  • the crystalline form I of the compound represented by formula (I) is characterized in that the DSC curve of the crystalline form I has an endothermic peak at 267.4°C ⁇ 3°C.
  • the DSC curve spectrum As shown in 23.
  • the preparation method of crystal form I of the compound represented by formula (I) includes: adding compound (I) to a mixed solution of dichloromethane, stirring at 5°C, suction filtration and drying. step.
  • the invention provides a pyridazine derivative 5-(6-chloro-5-((1S,2S)-2-phenylcyclopropyl)pyridazin-3-yl)pyrimidine-2,4(1H,3H )-diketone (compound (I)) free base crystal form J.
  • the crystal form J of the compound represented by formula (I) is characterized in that the X-ray powder diffraction spectrum has characteristic peaks at 2 ⁇ of 4.543°, 6.712°, 13.492° and 20.318°, 2 ⁇
  • the value error range is ⁇ 0.2°.
  • the crystalline form J of the compound represented by formula (I) is characterized in that the X-ray powder diffraction spectrum at 2 ⁇ is 4.543°, 6.712°, 13.492°, 20.318°, 23.461°, 26.520° There are characteristic peaks at , 27.226° and 34.227°, and the 2 ⁇ value error range is ⁇ 0.2°.
  • the crystal form J of the compound represented by formula (I) is characterized in that the X-ray powder diffraction spectrum has the characteristic peaks shown in Figure 25.
  • the preparation method of crystal form J of the compound represented by formula (I) includes: adding compound (I) to the TGA solution, and heating at a heating rate of 10°C/min in a nitrogen atmosphere. to 140.0°C, suction filtration and drying steps.
  • the invention provides a pyridazine derivative 5-(6-chloro-5-((1S,2S)-2-phenylcyclopropyl)pyridazin-3-yl)pyrimidine-2,4(1H,3H )-diketone (compound (I)) free base crystal form K.
  • the crystal form K of the compound represented by formula (I) is characterized by having characteristic peaks at 2 ⁇ of 4.119°, 4.608°, 12.526° and 14.347° in the X-ray powder diffraction spectrum, 2 ⁇
  • the value error range is ⁇ 0.2°.
  • the crystal form K of the compound represented by formula (I) is characterized in that the X-ray powder diffraction spectrum at 2 ⁇ is 4.119°, 4.608°, 12.526°, 13.654°, 13.996°, 14.347° There are characteristic peaks at , 23.478° and 25.156°, and the 2 ⁇ value error range is ⁇ 0.2°.
  • the crystal form K of the compound represented by formula (I) is characterized in that the X-ray powder diffraction spectrum has the characteristic peaks shown in Figure 26.
  • the preparation method of crystal form K of the compound represented by formula (I) includes: adding compound (I) to methyl isobutyl ketone solvent, stirring at 5°C, suction filtration and Drying step.
  • the present invention provides a pyridazine derivative 5-(6-chloro-5-((1S,2S)-2-phenylcyclopropyl)pyridazin-3-yl)pyrimidine-2,4 Sulfate crystal form, preparation method and application of (1H,3H)-diketone (compound (I)).
  • the sulfate crystal form L of the compound represented by formula (I) is characterized in that the X-ray powder diffraction spectrum has characteristic peaks at 2 ⁇ of 4.387, 8.711 and 17.402, and the 2 ⁇ value error range is ⁇ 0.2°.
  • the sulfate crystal form L of the compound represented by formula (I) is characterized in that the 2 ⁇ in the There is a characteristic peak at , and the 2 ⁇ value error range is ⁇ 0.2°.
  • the sulfate crystal form L of the compound represented by formula (I) is characterized in that the X-ray powder diffraction spectrum has the characteristic peaks shown in Figure 27.
  • the sulfate crystal form L of the compound represented by formula (I) is characterized in that the DSC curve of the crystal form L has an endothermic peak at 66.8°C ⁇ 3°C and an endothermic peak at 208.8°C ⁇ 3°C. There is an exothermic peak at °C.
  • its DSC curve is as shown in 28.
  • the preparation method of the sulfate crystal form L of the compound represented by formula (I) includes: adding compound (I) to acetone solvent, adding sulfuric acid dropwise, stirring at 25°C, and suction filtration. and drying steps.
  • the invention provides a crystal form A comprising a compound of formula (I), a crystal form B of a compound of formula (I), a crystal form C of a compound of formula (I), a crystal form D of a compound of formula (I), and a compound of formula (I).
  • the crystalline form I of the compound, the crystalline form J of the compound of formula (I), the crystalline form K of the compound of formula (I) or the sulfate crystalline form L of the compound of formula (I) account for more than 50% of the weight of
  • the present invention provides a pharmaceutical composition, which contains the above compound or the above crystal form, and optional pharmaceutically acceptable excipients.
  • the present invention also provides the use of the above-mentioned compound or the above-mentioned crystal form or the above-mentioned pharmaceutical composition in the preparation of CD73 inhibitors.
  • the present invention also provides the use of the above-mentioned compound or the above-mentioned crystal form or the above-mentioned crystalline composition or the above-mentioned pharmaceutical composition in the preparation of medicaments for preventing or treating diseases mediated by CD73 (such as tumors).
  • the present invention also provides a method for preventing or treating diseases mediated by CD73, which includes administering a therapeutically effective amount of the above-mentioned compound or the above-mentioned crystal form or the above-mentioned crystal composition or the above-mentioned pharmaceutical composition to a mammal in need, preferably a human.
  • the present invention also provides the use of the above-mentioned compound or the above-mentioned crystal form or the above-mentioned crystalline composition or the above-mentioned pharmaceutical composition in preventing or treating diseases mediated by CD73.
  • the present invention also provides the above-mentioned compound or the above-mentioned crystal form or the above-mentioned crystal composition or the above-mentioned pharmaceutical composition for preventing or treating diseases mediated by CD73.
  • the present invention also provides the above-mentioned compound or the above-mentioned crystal form or the above-mentioned crystal composition or the above-mentioned pharmaceutical composition for use as a CD73 inhibitor.
  • the present invention also provides the above-mentioned compound or the above-mentioned crystal form or the above-mentioned crystal composition or the above-mentioned pharmaceutical composition for use as a drug for preventing or treating diseases mediated by CD73.
  • the above-mentioned CD73-mediated diseases refer to tumors, and the tumors are selected from breast cancer, multiple myeloma, bladder cancer, endometrial cancer, gastric cancer, cervical cancer, rhabdomyosarcoma, non-small cell lung cancer, Cell lung cancer, small cell lung cancer, pleomorphic lung cancer, ovarian cancer, esophageal cancer, melanoma, colorectal cancer, hepatoma, head and neck tumors, hepatocellular carcinoma, myelodysplastic syndrome, malignant glioma, Prostate cancer, thyroid cancer, Schwann cell tumor, lung squamous cell carcinoma, lichenoid keratosis, synovial sarcoma, skin cancer, pancreatic cancer, testicular cancer, or liposarcoma.
  • the above-mentioned CD73 inhibitor refers to a drug for treating tumors, and the tumors are selected from breast cancer, multiple myeloma, bladder cancer, endometrial cancer, gastric cancer, cervical cancer, rhabdomyosarcoma, non-small cell lung cancer, Cell lung cancer, small cell lung cancer, pleomorphic lung cancer, ovarian cancer, esophageal cancer, melanoma, colorectal cancer, hepatoma, head and neck tumors, hepatocellular carcinoma, myelodysplastic syndrome, malignant glioma, Prostate cancer, thyroid cancer, Schwann cell tumor, lung squamous cell carcinoma, lichenoid keratosis, synovial sarcoma, skin cancer, pancreatic cancer, testicular cancer, or liposarcoma.
  • the tumors are selected from breast cancer, multiple myeloma, bladder cancer, endometrial cancer, gastric cancer, cervical cancer, rhabdomyo
  • the preparation process of the compound and crystal form disclosed by the invention is simple, and the crystal form is relatively stable, less affected by heat and humidity, has good pressure resistance, and is easy to prepare.
  • the compounds disclosed in the present invention and their crystal forms have good CD73 inhibitory activity; the crystal forms of the present invention have advantages in drug activity, hygroscopicity, stability, purity, ease of preparation, etc., to meet the needs of drug production, storage, and transportation. and preparation needs.
  • composition refers to a mixture of one or more compounds or crystal forms of the present application and pharmaceutically acceptable excipients.
  • the purpose of pharmaceutical compositions is to facilitate administration to an organism of the compounds of the present application.
  • pharmaceutically acceptable excipients refers to those excipients that have no obvious irritating effect on the organism and do not impair the biological activity and performance of the active compound. Suitable excipients are well known to those skilled in the art, such as carbohydrates, waxes, water-soluble and/or water-swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents, water, etc.
  • the pharmaceutical composition of the present invention can be prepared by combining the compounds and crystal forms of the present application with appropriate pharmaceutically acceptable excipients.
  • it can be formulated into solid, semi-solid, liquid or gaseous preparations, such as tablets, pills, capsules Agents, powders, granules, ointments, emulsions, suspensions, suppositories, injections, inhalants, gels, microspheres and aerosols, etc.
  • Typical routes of administration of the compounds of the present invention or crystalline forms or crystalline compositions or pharmaceutical compositions thereof include, but are not limited to, oral, rectal, topical, inhalation, parenteral, sublingual, intravaginal, intranasal, intraocular, intraperitoneal, intramuscular Intravenous, subcutaneous, and intravenous administration.
  • treatment generally refers to obtaining a desired pharmacological and/or physiological effect.
  • the effect may be therapeutic in terms of partial or complete stabilization or cure of the disease and/or side effects due to the disease.
  • treatment encompasses any treatment of a patient's disease that: (a) inhibits the symptoms of the disease, i.e., prevents their progression; or (b) alleviates the symptoms of the disease, i.e., causes regression of the disease or symptoms.
  • the term "effective amount” means (i) treating or preventing a specified disease, condition, or disorder, (ii) reducing, ameliorating, or eliminating one or more symptoms of a specified disease, condition, or disorder, or (iii) preventing or delaying An amount of a compound of the present application that is associated with the onset of one or more symptoms of a particular disease, condition, or disorder described in .
  • the amount of a compound of the present application that constitutes a "therapeutically effective amount” will vary depending on the compound, the disease state and its severity, the mode of administration, and the age of the mammal to be treated, but can be routinely determined by one skilled in the art. based on its own knowledge and the contents of this disclosure.
  • XRPD refers to X-ray powder diffraction.
  • DSC differential scanning calorimetry
  • mDSC modulated differential scanning calorimetry
  • TGA thermogravimetric analysis
  • Figure 1 is the XRPD pattern of compound (I) crystal form A
  • Figure 2 is the mDSC chart of compound (I) crystal form A
  • Figure 3 is a TGA diagram of compound (I) crystal form A
  • Figure 4 is the XRPD pattern of compound (I) crystal form B
  • Figure 5 is the mDSC chart of compound (I) crystal form B
  • Figure 6 is a TGA diagram of compound (I) crystal form B
  • Figure 7 is the XRPD pattern of compound (I) crystal form C
  • Figure 8 is a DSC chart of compound (I) crystal form C
  • Figure 9 is a TGA diagram of compound (I) crystal form C
  • Figure 10 is the XRPD pattern of compound (I) crystal form D
  • Figure 11 is a DSC chart of compound (I) crystal form D
  • Figure 12 is a TGA diagram of compound (I) crystal form D
  • Figure 13 is the XRPD pattern of compound (I) crystal form F
  • Figure 14 is a DSC chart of compound (I) crystal form F
  • Figure 15 is a TGA diagram of compound (I) crystal form F
  • Figure 16 is the XRPD pattern of compound (I) crystal form G
  • Figure 17 is a DSC chart of compound (I) crystal form G
  • Figure 18 is a TGA diagram of compound (I) crystal form G
  • Figure 19 is the XRPD pattern of compound (I) crystal form H
  • Figure 20 is a DSC chart of compound (I) crystal form H
  • Figure 21 is a TGA diagram of compound (I) crystal form H
  • Figure 22 is the XRPD pattern of compound (I) crystal form I;
  • Figure 23 is a DSC chart of compound (I) crystal form I
  • Figure 24 is a TGA diagram of compound (I) crystal form I
  • Figure 25 is the XRPD pattern of compound (I) crystal form J;
  • Figure 26 is the XRPD pattern of compound (I) crystal form K
  • Figure 27 is an XRPD pattern of compound (I) sulfate crystal form L;
  • Figure 28 is a DSC chart of compound (I) sulfate crystal form L;
  • Figure 29 is a TGA diagram of compound (I) sulfate crystal form L;
  • Figure 30 shows the XRPD overlay of crystal form A before and after compression
  • Figure 31 shows the XRPD overlay of crystal form B before and after compression
  • Figure 32 shows the XRPD overlay of crystal form D before and after compression
  • Figure 33 shows the absolute configuration of the compound (form B) in the crystal
  • Figure 34 is an ellipsoid diagram of the three-dimensional structure of the asymmetric unit of crystal form B;
  • Figure 35 is an ellipsoid diagram of the three-dimensional structure of a single molecule
  • Figure 36 is a projection of unit cell stacking along the a-axis direction.
  • the present invention will use the following examples to further illustrate the technical solution of the present invention.
  • the following examples are only used to illustrate specific implementations of the present invention so that those skilled in the art can understand the present invention, but are not used to limit the scope of the present invention.
  • technical means or methods that are not specifically described are conventional technical means or methods in the art.
  • the chiral compounds of the present invention can be separated and purified through chiral synthesis or conventional chiral columns.
  • n-BuLi n-butyllithium
  • Dioxane dioxane
  • DCM dichloromethane
  • DMSO dimethyl sulfoxide
  • DIEA or DIPEA N,N-diisopropylethylamine
  • TFA trifluoroacetic acid
  • TBSCl tert-butyldimethylsilyl chloride
  • DIC N,N-diisopropylcarbodiimide
  • PCC pyridinium chlorochromate
  • TBAF tetrabutylammonium fluoride trihydrate
  • THF tetrahydrofuran
  • MeOH methanol
  • DMAP 4-dimethylaminopyridine
  • DMF N,N-dimethylformamide
  • PdCl 2 (dppf) [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride
  • the mDSC spectrum of Form A is shown in Figure 2.
  • the endothermic peak peak is approximately 258.0°C.
  • Method 1 Add 50 mL of acetone solution to a 100 ml bottle, then add 5 g of the compound (I) prepared in Example 2, raise the temperature to 25°C, suspend and stir overnight, filter with suction to obtain the product, and obtain a white solid powder, which is dried under vacuum at room temperature for 6 hours, the final product was determined by XRPD, DSC and TGA to be compound (I) crystal form B.
  • the mDSC spectrum of Form B is shown in Figure 5.
  • the endothermic peak is approximately 244.9°C and the exothermic peak is approximately 245.2°C.
  • the TGA spectrum of Form B is shown in Figure 6. The sample has almost no weight loss before 150.0°C.
  • Method 2 Weigh 10 mg of compound (I), add it to 0.2 ml of ethanol, suspend and stir at 25°C for three days, filter with suction to obtain the product as a white solid powder, dry in vacuum at room temperature for 3 hours, and conduct XRPD, DSC and TGA It was determined that the final product was compound (I) crystal form B.
  • the DSC spectrum of Form C is basically as shown in Figure 8, with the exothermic peak peak at approximately 268.1°C.
  • the TGA spectrum of Form C is basically as shown in Figure 9, with a total weight loss of about 1.5% before 150.0°C.
  • the TGA spectrum of Form D is shown in Figure 12.
  • the total weight loss before 150.0°C is about 0.5%.
  • the DSC spectrum of Form F is shown in Figure 14.
  • the endothermic peak is approximately 47.6°C and the exothermic peak is approximately 276.9°C.
  • the DSC spectrum of Form G is shown in Figure 17.
  • the endothermic peaks are approximately 110.1°C, 128.0°C and 141.8°C, and the exothermic peaks are approximately 251.4°C.
  • the TGA spectrum of Form G is shown in Figure 18.
  • the weight loss before 130.0°C is 24.7%.
  • the DSC spectrum of Form H is shown in Figure 20.
  • the endothermic peaks are approximately 95.8°C, 107.2°C and 117.8°C, and the exothermic peaks are approximately 263.1°C.
  • the TGA spectrum of Form I is shown in Figure 24. It shows a total weight loss of about 0.8% before about 140°C.
  • the DSC spectrum of sulfate crystal form L is shown in Figure 28.
  • the endothermic peak is approximately 66.8°C and the exothermic peak is approximately 208.8°C.
  • the TGA spectrum of sulfate crystal form L is shown in Figure 29.
  • the total weight loss is about 3.9% before about 100.0°C.
  • the stability of the crystalline forms of the invention was determined.
  • the crystalline form A and crystalline form B of compound (I) were placed under the conditions of high temperature 60°C, high humidity 92.5%RH, 40°C/75%RH and 25°C/60%RH respectively for stability testing.
  • On the 0th day take samples on the 7th, 14th and 30th days. The samples taken are tested for relevant substances and compared with the initial data. The comparison results show that both crystal form A and crystal form B of compound (I) have good chemical stability.
  • Example 15 Determination of dynamic moisture adsorption (DVS)
  • the dynamic adsorption instrument detection equipment and method of the present invention are shown in Table 19.
  • the specific data are shown in Table 20.
  • the crystal forms A, B, C, and D after DVS testing have not changed.
  • Structural analysis The direct method (Shelxs97) was used to analyze the crystal structure.
  • the number of asymmetric units in the unit cell Z 1.
  • the least squares method was used to correct the structural parameters and identify atomic types, and the geometric calculation method was used to obtain the positions of all hydrogen atoms.
  • the stoichiometric formula of the asymmetric unit was finally determined to be 2(C 17 H 13 N 4 O 2 Cl), the calculated molecular weight of a single molecule was 340.76, and the calculated crystal density was 1.438g/cm 3 .
  • the absolute configuration of the compound in the crystal can be determined as shown in Figure 33. In the crystalline state, hydrogen bonds and van der Waals forces maintain a stable arrangement in space between molecules.
  • the three-dimensional structure ellipsoid diagram of the asymmetric unit is shown in Figure 34
  • the three-dimensional structure ellipsoid diagram of a single molecule is shown in Figure 35
  • the unit cell stacking projection along the a-axis direction is shown in Figure 36.
  • TM buffer 25mM Tris, 5mM MgCl 2 , pH 7.5
  • TM buffer prepares compound solutions with gradient concentrations.
  • the final concentration of the compound is 20000, 6666.7, 2222.2, 740.7, 246.9, 82.3, 27.4, 9.1, 3.0, 1.0, 0.3, 0nM (the final concentration of DMSO is 0.625%).
  • Inhibition percentage (1-reading/maximum value)*100.
  • Maximum is the DMSO control.
  • Curve fitting was performed using GraphPad Prism software and IC 50 values were obtained.
  • mice Using mice as test animals, the LC/MS/MS method was used to determine the drug concentration in the plasma of mice at different times after intragastric administration of the compounds of the examples. Study the pharmacokinetic behavior of the compound of the present invention in mice and evaluate its pharmacokinetic characteristics.
  • mice Use healthy Balb/C female mice (about 20g) purchased from Vitong Lever Laboratory Animal Co., Ltd. to conduct a single PK study in mice (PO 10mg/kg). About 1 hour before administration, weigh a certain amount of the drug and add 5% DMSO and 95% hydroxypropyl beta-cyclodextrin (HP- ⁇ -CD) solution to prepare a colorless and clear solution.
  • HP- ⁇ -CD solution is a 20% HP- ⁇ -CD aqueous solution prepared by adding HP- ⁇ -CD powder to 0.9% physiological saline.
  • the intragastric administration was carried out at a volume of 10 mL/kg, and blood was collected from the orbital venous plexus of the mice.
  • the blood collection time points were as follows: before administration and at 0.25, 0.5, 1.0, 2.0, 4.0, 7.0, 24.0 after administration. hour, take 100uL of whole blood at each time point into a K 2 EDTA anticoagulant tube, centrifuge the collected whole blood sample at 4000 rpm for 10 minutes, separate the plasma and store it in a -80°C refrigerator.
  • Cell culture Resuscitate the cells and culture them in a 37°C, 5% CO2 incubator. Observe that the cells are in good growth status. Passage for at least two generations and culture until the cell confluence is 80%-90%. See Table 23 for the culture medium and cell names.
  • Compound preparation Weigh the crystal form B respectively, compare with compound D1, convert the content, add the corresponding volume of DMSO, prepare the stock solution, vortex and mix until clear.
  • a) Configure the diluent of the sample to be tested use DMSO to perform a 3-fold gradient dilution of the 20mM DMSO storage solution of the crystalline form B of the test compound and the comparison compound D1, with a total of 11 concentration points.
  • DMSO to dilute the samples of each concentration. 6. Dilute 25 times, and then dilute the sample of each concentration 40 times with enzymatic buffer to obtain a sample dilution 4 times the final concentration.
  • the concentration of DMSO in the sample diluent is 2.5%, and the final concentration of DMSO in the detection system is 0.625%.
  • e) Use enzymatic buffer to prepare an ATP diluent with a concentration of 130 ⁇ M. According to the detection layout, add 50 ⁇ L of ATP diluent and 100 ⁇ L of CellTiter-Glo working solution to each well of a 96-well cell culture plate containing 50 ⁇ L of supernatant, and mix by shaking. After homogenization, incubate at room temperature for 10 minutes in the dark.
  • IC 50 refers to the relative half inhibitory concentration, that is, the compound concentration corresponding to half of the inhibition rate between the highest and lowest inhibition rates in the fitted curve. The results are shown in Table 29.
  • Cell culture Resuscitate the cells and culture them in a 37°C, 5% CO2 incubator. Observe that the cells are in good growth status. Passage for at least two generations and culture until the cell confluence is 80%-90%. See Table 24 for cell names and culture media.
  • CHO-K1 cells seed CHO-K1 cells in a cell culture flask.
  • the plasmid transfection system is: 15 ⁇ g plasmid + 24 ⁇ L Lipo8000 + 750 ⁇ L serum-free MEM. Add this transfection system to a cell culture bottle containing fresh culture medium, mix gently, and then place the cells in a cell incubator to continue culturing. The next day after transfection, the medium was replaced with fresh culture medium and cultured for 72 hours to obtain CHO-K1-hCD73 cells (overexpressing human CD73) for subsequent experiments.
  • Compound preparation Weigh the crystal form B respectively, compare with compound D1, convert the content, add the corresponding volume of DMSO, prepare the stock solution, vortex and mix until clear.
  • a) Configure the diluent of the sample to be tested Use DMSO to perform a 3-fold gradient dilution of the 20mM DMSO storage solution of the crystalline form B of the test compound and the comparison compound D1, with a total of 11 concentration points. First, use DMSO to dilute the sample of each concentration 6.25 times. Dilute, and then use enzymatic buffer to dilute the sample of each concentration 40 times to obtain a sample dilution 4 times the final concentration. The concentration of DMSO in the sample diluent is 2.5%, and the final concentration of DMSO in the detection system is 0.625%.
  • e) Use enzymatic buffer to prepare an ATP diluent with a concentration of 130 ⁇ M. According to the detection layout, add 50 ⁇ L of ATP diluent and 100 ⁇ L of CellTiter-Glo working solution to each well of a 96-well cell culture plate containing 50 ⁇ L of supernatant, and shake. Mix well and incubate at room temperature for 10 minutes away from light.
  • IC 50 refers to the relative half inhibitory concentration, that is, the compound concentration corresponding to half of the inhibition rate between the highest and lowest inhibition rates in the fitted curve. The results are shown in Table 29.
  • the plasma formula is shown in Table 27:
  • the substrate mixture formula is shown in Table 28:
  • test substance plasma sample Take 1.5 ⁇ L of the test substance plasma sample and place it on the Nanodrop detection base, detect the protein concentration of the test substance plasma sample, and then use the CD73 enzyme reaction buffer to dilute the plasma sample to 0.5 mg/mL.
  • the crystal form in the present invention has high inhibitory activity on both tumor cell CD73 enzyme activity and soluble CD73 enzyme activity.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及一种哒嗪类衍生物5-(6-氯-5-((1S，2S)-2-苯基环丙基)哒嗪-3-基)嘧啶-2,4(1H，3H)-二酮游离碱及其盐的晶型、制备方法及其应用。

Description

一种哒嗪类衍生物的晶型、制备方法及其应用 技术领域
本发明涉及一种哒嗪类衍生物5-(6-氯-5-((1S，2S)-2-苯基环丙基)哒嗪-3-基)嘧啶-2,4(1H，3H)-二酮的晶型、制备方法及其应用。
背景技术
胞外5'-核苷酸酶(ecto-5'-nucleotidase,CD73)是一种细胞膜上的糖蛋白，在多种细胞类型的细胞膜表面存在，包括内皮细胞、淋巴细胞、基质细胞和肿瘤细胞等。CD73能够催化细胞外5'-磷酸腺苷(5'-AMP)生成腺苷，而腺苷可诱导免疫抑制效应，促进肿瘤增殖和/或转移。此外，CD73还能够以非免疫相关机制促进肿瘤生成，如促进肿瘤血管生成、促进肿瘤细胞对细胞外基质蛋白的粘附等。临床上，CD73高水平表达与多种癌症类型的淋巴结转移和不良预后相关，已发现CD73是前列腺癌和三阴性乳腺癌患者的独立预后因素。
化合物(5-(6-氯-5-((1S，2S)-2-苯基环丙基)哒嗪-3-基)嘧啶-2,4(1H，3H)-二酮)是本公司研发的一种新型结构的小分子CD73抑制剂，其对于CD73具有明显的抑制作用；药物研发中，晶型将直接影响药物的稳定性，生物利用度及生产工艺，因而研究和控制晶型在药物研发中至关重要；系统的药物晶型筛选，评估和选择，是开发高质量药物以及把药物价值最大化的一个重要环节。
发明内容
一方面，本发明提供一种哒嗪类衍生物5-(6-氯-5-((1S，2S)-2-苯基环丙基)哒嗪-3-基)嘧啶-2,4(1H，3H)-二酮(化合物(Ⅰ))游离碱的晶型、制备方法及其应用。
本发明提供一种哒嗪类衍生物5-(6-氯-5-((1S，2S)-2-苯基环丙基)哒嗪-3-基)嘧啶-2,4(1H，3H)-二酮(化合物(Ⅰ))游离碱晶型A。
一些实施方式中，所述式(I)所示化合物的晶型A，其特征在于，X射线粉末衍射谱图中在2θ为4.521°、7.268°、11.930°、15.837°和16.946°处具有特征峰，2θ值误差范围为±0.2°。
一些实施方式中，所述式(I)所示化合物的晶型A，其特征在于，X射线粉末衍射谱图中在2θ为4.521°、7.268°、11.442°、11.930°、15.837°、16.946°和22.717°处具有特征峰，2θ值误差范围为±0.2°。
一些实施方式中，所述式(I)所示化合物的晶型A，其特征在于，X射线粉末衍射谱图中在2θ为4.521°、7.268°、11.442°、11.930°、15.141°、15.518°、15.837°、16.946°、22.717°、23.867°和25.581°处具有特征峰，2θ值误差范围为±0.2°。
一些实施方式中，所述式(I)所示化合物的晶型A，其特征在于，X射线粉末衍射谱图具有图1所示的特征峰。
一些实施方式中，所述式(I)所示化合物的晶型A，其特征在于，所述晶型的mDSC曲线在258.0℃±3℃处有一个吸热峰，优选地，其mDSC曲线图谱如2所示。
一些实施方式中，所述式(I)所示化合物的晶型A的制备方法，所述制备方法包括：向丙酮溶液中加入化合物(I)，升温到50℃，搅拌，抽滤及干燥步骤。
本发明提供一种哒嗪类衍生物5-(6-氯-5-((1S，2S)-2-苯基环丙基)哒嗪-3-基)嘧啶-2,4(1H，3H)-二酮(化合物(Ⅰ))游离碱晶型B。
一些实施方式中，所述式(I)所示化合物的晶型B，其特征在于，X射线粉末衍射谱图中在2θ为4.789°、15.673°和24.161°处具有特征峰，2θ值误差范围为±0.2°。
一些实施方式中，所述式(I)所示化合物的晶型B，其特征在于，X射线粉末衍射谱图中在2θ为4.789°、9.598°、15.673°和24.161°处具有特征峰，2θ值误差范围为±0.2°。
一些实施方式中，所述式(I)所示化合物的晶型B，其特征在于，X射线粉末衍射谱图中在2θ为4.789°、9.598°、14.424°、15.673°和24.161°处具有特征峰，2θ值误差范围为±0.2°。
一些实施方式中，所述式(I)所示化合物的晶型B，其特征在于，X射线粉末衍射谱图中在2θ为4.789°、9.598°、10.076°、14.424°、15.275°、15.673°、19.262°、24.161°处具有特征峰，2θ值误差范围为±0.2°。
一些实施方式中，所述式(I)所示化合物的晶型B，其特征在于，X射线粉末衍射谱图中在2θ为4.789°、9.598°、10.076°、14.424°、15.275°、15.673°、19.262°、19.714°、19.989°、20.229°、24.161°和27.193°处具有特征峰，2θ值误差范围为±0.2°。
一些实施方式中，所述式(I)所示化合物的晶型B，其特征在于，X射线粉末衍射谱图具有图4所示的特征峰。
一些实施方式中，所述式(I)所示化合物的晶型B，其特征在于，所述晶型B的mDSC曲线在228.7℃±3℃和244.9℃±3℃处有一个吸热峰，在245.2℃±3℃处有一个放热峰，优选地，其DSC曲线图谱如5所示。
一些实施方式中，所述式(I)所示化合物的晶型B的制备方法，所述制备方法包括：向丙酮溶液中加入化合物(I)，升温到25℃，搅拌，抽滤及干燥步骤。
一些实施方式中，所述式(I)所示化合物的晶型B的制备方法，所述制备方法包括：向乙醇溶液中加入化合物(I)，升温到25℃，搅拌，抽滤及干燥步骤。
本发明提供一种哒嗪类衍生物5-(6-氯-5-((1S，2S)-2-苯基环丙基)哒嗪-3-基)嘧啶-2,4(1H，3H)-二酮(化合物(Ⅰ))游离碱晶型C。
一些实施方式中，所述式(I)所示化合物的晶型C，其特征在于，X射线粉末衍射谱图中在2θ为3.854°、5.250°、7.126°、14.870°、16.357°、19.629°、21.613°、和21.982°处具有特征峰，2θ值误差范围为±0.2°。
一些实施方式中，所述式(I)所示化合物的晶型C，其特征在于，X射线粉末衍射谱图中在2θ为3.854°、5.250°、7.126°、14.870°、15.925°、16.357°、18.581°、19.629°、21.613°和21.982°处具有特征峰，2θ值误差范围为±0.2°。
一些实施方式中，所述式(I)所示化合物的晶型C，其特征在于，X射线粉末衍射谱图中在2θ为3.854°、5.250°、7.126°、14.870°、15.925°、16.357°、18.581°、19.629°、21.613°、21.982°、23.831°、25.578°、30.069°、33.684°和36.482°处具有特征峰，2θ值误差范围为±0.2°。
一些实施方式中，所述式(I)所示化合物的晶型C，其特征在于，X射线粉末衍射谱图具有图7所示的特征峰。
一些实施方式中，所述式(I)所示化合物的晶型C，其特征在于，所述晶型C的DSC曲线在268.1℃±3℃处有一个放热峰，优选地，其DSC曲线图谱如8所示。
一些实施方式中，所述式(I)所示化合物的晶型C的制备方法，所述制备方法包括：向四氢呋喃/水的混合溶液中加入化合物(I)，升温到50℃，搅拌，降温，抽滤，收集滤液，滤液中加入正庚烷，及再次降温抽滤步骤。
一些实施方式中，所述式(I)所示化合物的晶型C的制备方法，所述四氢呋喃与水的体积比为14:1。
本发明提供一种哒嗪类衍生物5-(6-氯-5-((1S，2S)-2-苯基环丙基)哒嗪-3-基)嘧啶-2,4(1H，3H)-二酮(化合物(Ⅰ))游离碱晶型D。
一些实施方式中，所述式(I)所示化合物的晶型D，其特征在于，X射线粉末衍射谱图中在2θ为4.661°、12.132°、15.653°、23.500°、26.514°和27.356°处具有特征峰，2θ值误差范围为±0.2°。
一些实施方式中，所述式(I)所示化合物的晶型D，其特征在于，X射线粉末衍射谱图中在2θ为4.661°、12.132°、14.033°、15.653°、17.891°、19.937°、23.500°、24.942°、26.514°和27.356°处具有特征峰，2θ值误差范围为±0.2°。
一些实施方式中，所述式(I)所示化合物的晶型D，其特征在于，X射线粉末衍射谱图具有图10所示的特征峰。
一些实施方式中，所述式(I)所示化合物的晶型D，其特征在于，所述晶型D的DSC曲线在274.5℃±3℃处有一个放热峰，优选地，其DSC曲线图谱如11所示。
一些实施方式中，所述式(I)所示化合物的晶型D的制备方法，所述制备方法包括：向二氯甲烷溶液中加入化合物(I)，升温到50℃，搅拌，抽滤及干燥步骤。
本发明提供一种哒嗪类衍生物5-(6-氯-5-((1S，2S)-2-苯基环丙基)哒嗪-3-基)嘧啶-2,4(1H，3H)-二酮(化合物(Ⅰ))游离碱晶型F。
一些实施方式中，所述式(I)所示化合物的晶型F，其特征在于，X射线粉末衍射谱图中在2θ为4.525°、6.885°、11.848°、14.337°、16.594°和24.492°处具有特征峰，2θ值误差范围为±0.2°。
一些实施方式中，所述式(I)所示化合物的晶型F，其特征在于，X射线粉末衍射谱图中在2θ为4.525°、6.885°、11.021°、11.848°、14.337°、16.594°、22.965°和24.492°处具有特征峰，2θ值误差范围为±0.2°。
一些实施方式中，所述式(I)所示化合物的晶型F，其特征在于，X射线粉末衍射谱图中在2θ为4.525°、5.471°、6.885°、9.492°、11.021°、11.848°、13.311°、14.337°、14.893°、16.594°、17.182°、18.276°、22.965°、24.492°和25.446°处具有特征峰，2θ值误差范围为±0.2°。
一些实施方式中，所述式(I)所示化合物的晶型F，其特征在于，X射线粉末衍射谱图具有图13所示的特征峰。
一些实施方式中，所述式(I)所示化合物的晶型F，其特征在于，所述晶型F的DSC曲线在47.6℃±3℃处有一个吸热峰，在276.9℃±3℃处有一个放热峰，优选地，其DSC曲线图谱如14所示。
一些实施方式中，所述式(I)所示化合物的晶型F的制备方法，所述制备方法包括：向甲醇溶液中加入化合物(I)，升温到50℃，搅拌，抽滤及干燥步骤。
本发明提供一种哒嗪类衍生物5-(6-氯-5-((1S，2S)-2-苯基环丙基)哒嗪-3-基)嘧啶-2,4(1H，3H)-二酮(化合物(I)游离碱晶型G。
一些实施方式中，所述式(I)所示化合物的晶型G，其特征在于，X射线粉末衍射谱图中在2θ为5.986°、6.956°、14.011°、17.552°、19.157°和24.343°处具有特征峰，2θ值误差范围为±0.2°。
一些实施方式中，所述式(I)所示化合物的晶型G，其特征在于，X射线粉末衍射谱图中在2θ为5.986°、6.956°、14.011°、17.552°、19.157°、22.300°、23.443°和24.343°处具有特征峰，2θ值误差范围为±0.2°。
一些实施方式中，所述式(I)所示化合物的晶型G，其特征在于，X射线粉末衍射谱图中在2θ为5.986°、6.956°、14.011°、14.354°、17.552°、18.195°、19.157°、19.509°、19.922°、22.300°、23.443°、24.343°、25.928°、29.391°和30.476°处具有特征峰，2θ值误差范围为±0.2°。
一些实施方式中，所述式(I)所示化合物的晶型G，其特征在于，X射线粉末衍射谱图具有图16所示的特征峰。
一些实施方式中，所述式(I)所示化合物的晶型G，其特征在于，所述晶型G的DSC曲线在110.1℃±3℃，128.0℃±3℃和141.8℃±3℃处有吸热峰，在251.4℃±3℃处有一个放热峰，优选地，其DSC曲线图谱如17所示。
一些实施方式中，所述式(I)所示化合物的晶型G的制备方法，所述制备方法包括：向二甲基亚砜/丁酮的混合溶液中加入化合物(I)，升温到50℃，搅拌，抽滤及干燥步骤。
一些实施方式中，所述式(I)所示化合物的晶型G的制备方法，所述二甲基亚砜/丁酮的混合溶液中二甲基亚砜：丁酮的体积比为1：1。
本发明提供一种哒嗪类衍生物5-(6-氯-5-((1S，2S)-2-苯基环丙基)哒嗪-3-基)嘧啶-2,4(1H，3H)-二酮(化合物(Ⅰ))游离碱晶型H。
一些实施方式中，所述式(I)所示化合物的晶型H，其特征在于，X射线粉末衍射谱图中在2θ为11.838°、16.771°、21.451°和22.524°处具有特征峰，2θ值误差范围为±0.2°。
一些实施方式中，所述式(I)所示化合物的晶型H，其特征在于，X射线粉末衍射谱图中在2θ为11.838°、16.771°、17.251°、21.451°、22.524°、23.494°和26.982°处具有特征峰，2θ值误差范围为±0.2°。
一些实施方式中，所述式(I)所示化合物的晶型H，其特征在于，X射线粉末衍射谱图中在2θ为9.087°、9.518°、10.650°、11.838°、12.105°、16.771°、17.251°、19.655°、19.831°、 20.328°、21.451°、22.524°、23.494°、24.783°、26.982°和27.507°处具有特征峰，2θ值误差范围为±0.2°。
一些实施方式中，所述式(I)所示化合物的晶型H，其特征在于，X射线粉末衍射谱图具有图19所示的特征峰。
一些实施方式中，所述式(I)所示化合物的晶型H，其特征在于，所述晶型H的DSC曲线在95.8℃±3℃，107.2℃±3℃和117.8℃±3℃处有吸热峰，在263.1℃±3℃处有一个放热峰，优选地，其DSC曲线图谱如20所示。
一些实施方式中，所述式(I)所示化合物的晶型H的制备方法，所述制备方法包括：向二甲基亚砜/乙酸乙酯的混合溶液中加入化合物(I)，升温到50℃，搅拌，抽滤及干燥步骤。
一些实施方式中，所述式(I)所示化合物的晶型G的制备方法，所述二甲基亚砜/乙酸乙酯的混合溶液中二甲基亚砜：丁酮的体积比为1：9。
本发明提供一种哒嗪类衍生物5-(6-氯-5-((1S，2S)-2-苯基环丙基)哒嗪-3-基)嘧啶-2,4(1H，3H)-二酮(化合物(I))游离碱晶型I。
一些实施方式中，所述式(I)所示化合物的晶型I，其特征在于，X射线粉末衍射谱图中在2θ为3.999°、6.693°、13.476°和20.308°处具有特征峰，2θ值误差范围为±0.2°。
一些实施方式中，所述式(I)所示化合物的晶型I，其特征在于，X射线粉末衍射谱图中在2θ为3.999°、5.042°、6.693°、13.476°、20.308°、26.507°和27.212°处具有特征峰，2θ值误差范围为±0.2°。
一些实施方式中，所述式(I)所示化合物的晶型I，其特征在于，X射线粉末衍射谱图中在2θ为3.999°、5.042°、6.693°、13.476°、16.656°、20.308°、22.481°、23.476°、26.507°、27.212°、27.852°、28.944°和34.216°处具有特征峰，2θ值误差范围为±0.2°。
一些实施方式中，所述式(I)所示化合物的晶型I，其特征在于，X射线粉末衍射谱图具有图22所示的特征峰。
一些实施方式中，所述式(I)所示化合物的晶型I，其特征在于，所述晶型I的DSC曲线在267.4℃±3℃处有吸热峰，优选地，其DSC曲线图谱如23所示。
一些实施方式中，所述式(I)所示化合物的晶型I的制备方法，所述制备方法包括：向二氯甲烷的混合溶液中加入化合物(I)，5℃搅拌，抽滤及干燥步骤。
本发明提供一种哒嗪类衍生物5-(6-氯-5-((1S，2S)-2-苯基环丙基)哒嗪-3-基)嘧啶-2,4(1H，3H)-二酮(化合物(I))游离碱晶型J。
一些实施方式中，所述式(I)所示化合物的晶型J，其特征在于，X射线粉末衍射谱图中在2θ为4.543°、6.712°、13.492°和20.318°处具有特征峰，2θ值误差范围为±0.2°。
一些实施方式中，所述式(I)所示化合物的晶型J，其特征在于，X射线粉末衍射谱图中在2θ为4.543°、6.712°、13.492°、20.318°、23.461°、26.520°、27.226°和34.227°处具有特征峰，2θ值误差范围为±0.2°。
一些实施方式中，所述式(I)所示化合物的晶型J，其特征在于，X射线粉末衍射谱图具有图25所示的特征峰。
一些实施方式中，所述式(I)所示化合物的晶型J的制备方法，所述制备方法包括：向TGA溶液中加入化合物(I)，氮气氛围下以10℃/min的升温速率加热至140.0℃，抽滤及干燥步骤。
本发明提供一种哒嗪类衍生物5-(6-氯-5-((1S，2S)-2-苯基环丙基)哒嗪-3-基)嘧啶-2,4(1H，3H)-二酮(化合物(I))游离碱晶型K。
一些实施方式中，所述式(I)所示化合物的晶型K，其特征在于，X射线粉末衍射谱图中在2θ为4.119°、4.608°、12.526°和14.347°处具有特征峰，2θ值误差范围为±0.2°。
一些实施方式中，所述式(I)所示化合物的晶型K，其特征在于，X射线粉末衍射谱图中在2θ为4.119°、4.608°、12.526°、13.654°、13.996°、14.347°、23.478°和25.156°处具有特征峰，2θ值误差范围为±0.2°。
一些实施方式中，所述式(I)所示化合物的晶型K，其特征在于，X射线粉末衍射谱图具有图26所示的特征峰。
一些实施方式中，所述式(I)所示化合物的晶型K的制备方法，所述制备方法包括：向甲基异丁基酮溶剂中加入化合物(I)，5℃搅拌，抽滤及干燥步骤。
另一方面，本发明提供一种哒嗪类衍生物5-(6-氯-5-((1S，2S)-2-苯基环丙基)哒嗪-3-基)嘧啶-2,4(1H，3H)-二酮(化合物(I))的硫酸盐晶型、制备方法及其应用。
一些实施方式中，所述式(I)所示化合物的硫酸盐晶型L，其特征在于，X射线粉末衍射谱图中在2θ为4.387、8.711和17.402处具有特征峰，2θ值误差范围为±0.2°。
一些实施方式中，所述式(I)所示化合物的硫酸盐晶型L，其特征在于，X射线粉末衍射谱图中在2θ为4.387、8.711、13.049、16.448、17.402、19.606、27.029和35.138处具有特征峰，2θ值误差范围为±0.2°。
一些实施方式中，所述式(I)所示化合物的硫酸盐晶型L，其特征在于，X射线粉末衍射谱图具有图27所示的特征峰。
一些实施方式中，所述式(I)所示化合物的硫酸盐晶型L，其特征在于，所述晶型L的DSC曲线在66.8℃±3℃有一个吸热峰，在208.8℃±3℃处有一个放热峰，优选地，其DSC曲线图谱如28所示。
一些实施方式中，所述式(I)所示化合物的硫酸盐晶型L的制备方法，所述制备方法包括：向丙酮溶剂中加入化合物(I)，滴加硫酸，25℃搅拌，抽滤及干燥步骤。
本发明所述式(I)所示化合物的晶型A、晶型B、晶型C、晶型D、晶型F、晶型G、晶型H、晶型I、晶型J、晶型K以及硫酸盐晶型L，其X射线粉末衍射图均使用Cu靶的Kα谱线测得，其波长λ为
本发明提供了一种包含式(I)化合物的晶型A、式(I)化合物的晶型B、式(I)化合物的晶型C、式(I)化合物的晶型D、式(I)化合物的晶型F、式(I)化合物的晶型G、式(I)化合物的晶型H、式(I)化合物的晶型I、式(I)化合物的晶型J、式(I)化合物的晶型K，或者式(I)化合物硫酸盐晶型L的结晶组合物，其中所述式(I)化合物的晶型A、式(I)化合物的晶型B、式(I)化合物的晶型C、式(I)化合物的晶型D、式(I)化合物的晶型F、式(I)化合物的晶型G、式(I)化合物的晶型H、式(I)化合物的晶型I、式(I)化合物的晶型J、式(I)化合物的晶型K或式(I)化合物硫酸盐晶型L占所述结晶组合物重量的50％以上，较好是75％以上，更好是90％以上，最好是95％以上。所述各结晶组合物中，还可能分别含有少量的式(I)化合物的其他结晶或非结晶形式。
本发明提供一种药物组合物，其包含上述化合物或上述晶型、以及任选的药学上可接受的辅料。
本发明还提供上述化合物或上述晶型或上述药物组合物在制备CD73抑制剂中的用途。
本发明还提供上述化合物或上述晶型或上述结晶组合物或上述药物组合物在制备用于预防或治疗由CD73介导的疾病(例如肿瘤)的药物中的用途。
本发明还提供一种预防或治疗由CD73介导的疾病的方法，包括对有需要的哺乳动物、优选人类给予治疗有效量的上述化合物或上述晶型或上述结晶组合物或上述药物组合物。
本发明还提供上述化合物或上述晶型或上述结晶组合物或上述药物组合物在预防或治疗由CD73介导的疾病中的用途。
本发明还提供了一种用于预防或治疗由CD73介导的疾病的上述化合物或上述晶型或上述结晶组合物或上述药物组合物。
本发明还提供作为CD73抑制剂使用的上述化合物或上述晶型或上述结晶组合物或上述药物组合物。
本发明还提供作为预防或治疗由CD73介导的疾病的药物使用的上述化合物或上述晶型或上述结晶组合物或上述药物组合物。
在本发明的一些方案中，上述由CD73介导的疾病是指肿瘤，所述肿瘤选自乳腺癌、多发性骨髓瘤、膀胱癌、子宫内膜癌、胃癌、宫颈癌、横纹肌肉瘤、非小细胞肺癌、小细胞肺癌、多形性肺癌、卵巢癌、食管癌、黑色素瘤、结肠直肠癌、肝细胞瘤、头颈部肿瘤、肝胆管细胞癌、骨髓增生异常综合征、恶性胶质瘤、前列腺癌、甲状腺癌、徐旺氏细胞瘤、肺鳞状细胞癌、苔藓样角化病、滑膜肉瘤、皮肤癌、胰腺癌、睾丸癌或脂肪肉瘤。
在本发明的一些方案中，上述CD73抑制剂是指治疗肿瘤的药物，所述肿瘤选自乳腺癌、多发性骨髓瘤、膀胱癌、子宫内膜癌、胃癌、宫颈癌、横纹肌肉瘤、非小细胞肺癌、小细胞肺癌、多形性肺癌、卵巢癌、食管癌、黑色素瘤、结肠直肠癌、肝细胞瘤、头颈部肿瘤、肝胆管细胞癌、骨髓增生异常综合征、恶性胶质瘤、前列腺癌、甲状腺癌、徐旺氏细胞瘤、肺鳞状细胞癌、苔藓样角化病、滑膜肉瘤、皮肤癌、胰腺癌、睾丸癌或脂肪肉瘤。
本发明公开的化合物及晶型的制备工艺简单，且晶型较稳定、受热和湿度影响较小，具有较好的抗压性能，便于制剂。本发明公开的化合物及其晶型具有良好的CD73的抑制活性；本发明的晶型在药物活性、吸湿性、稳定性、纯度、易制备等方面具备优势，以满足药物在生产、储存、运输和制剂等方面的需求。
术语“药物组合物”是指一种或多种本申请的化合物或晶型与药学上可接受的辅料组成的混合物。药物组合物的目的是有利于对有机体给予本申请的化合物。
术语“药学上可接受的辅料”是指对有机体无明显刺激作用，而且不会损害该活性化合物的生物活性及性能的那些辅料。合适的辅料是本领域技术人员熟知的，例如碳水化合物、蜡、水溶性和/或水可膨胀的聚合物、亲水性或疏水性材料、明胶、油、溶剂、水等。
本发明的药物组合物可通过将本申请的化合物、晶型与适宜的药学上可接受的辅料组合而制备，例如可配制成固态、半固态、液态或气态制剂，如片剂、丸剂、胶囊剂、粉剂、颗粒剂、膏剂、乳剂、悬浮剂、栓剂、注射剂、吸入剂、凝胶剂、微球及气溶胶等。
给予本发明化合物或晶型或结晶组合物或其药物组合物的典型途径包括但不限于口服、直肠、局部、吸入、肠胃外、舌下、阴道内、鼻内、眼内、腹膜内、肌内、皮下、静脉内给药。
术语“治疗”一般是指获得需要的药理和/或生理效应。该效应根据部分或完全稳定或治愈疾病和/或由于疾病产生的副作用，可以是治疗性的。本文使用的“治疗”涵盖了对患者疾病的任何治疗，包括：(a)抑制疾病的症状，即阻止其发展；或(b)缓解疾病的症状，即，导致疾病或症状退化。
术语“有效量”意指(i)治疗或预防特定疾病、病况或障碍，(ii)减轻、改善或消除特定疾病、病况或障碍的一种或多种症状，或(iii)预防或延迟本文中所述的特定疾病、病况或障碍的一种或多种症状发作的本申请化合物的用量。构成“治疗有效量”的本申请化合物的量取决于该化合物、疾病状态及其严重性、给药方式以及待被治疗的哺乳动物的年龄而改变，但可例行性地由本领域技术人员根据其自身的知识及本公开内容而确定。
术语“XRPD”是指X射线粉末衍射。
术语“DSC”是指差示扫描量热法。
术语“mDSC”是指调制差示扫描量热法。
术语“TGA”是指热重分析法。
附图说明
图1为化合物(Ⅰ)晶型A的XRPD图；
图2为化合物(Ⅰ)晶型A的mDSC图；
图3为化合物(Ⅰ)晶型A的TGA图；
图4为化合物(Ⅰ)晶型B的XRPD图；
图5为化合物(Ⅰ)晶型B的mDSC图；
图6为化合物(Ⅰ)晶型B的TGA图；
图7为化合物(Ⅰ)晶型C的XRPD图；
图8为化合物(Ⅰ)晶型C的DSC图；
图9为化合物(Ⅰ)晶型C的TGA图；
图10为化合物(Ⅰ)晶型D的XRPD图；
图11为化合物(Ⅰ)晶型D的DSC图；
图12为化合物(Ⅰ)晶型D的TGA图；
图13为化合物(Ⅰ)晶型F的XRPD图；
图14为化合物(Ⅰ)晶型F的DSC图；
图15为化合物(Ⅰ)晶型F的TGA图；
图16为化合物(Ⅰ)晶型G的XRPD图；
图17为化合物(Ⅰ)晶型G的DSC图；
图18为化合物(Ⅰ)晶型G的TGA图；
图19为化合物(Ⅰ)晶型H的XRPD图；
图20为化合物(Ⅰ)晶型H的DSC图；
图21为化合物(Ⅰ)晶型H的TGA图；
图22为化合物(Ⅰ)晶型I的XRPD图；
图23为化合物(Ⅰ)晶型I的DSC图；
图24为化合物(Ⅰ)晶型I的TGA图；
图25为化合物(Ⅰ)晶型J的XRPD图；
图26为化合物(Ⅰ)晶型K的XRPD图；
图27为化合物(Ⅰ)硫酸盐晶型L的XRPD图；
图28为化合物(Ⅰ)硫酸盐晶型L的DSC图；
图29为化合物(Ⅰ)硫酸盐晶型L的TGA图；
图30为晶型A受压前后的XRPD叠图；
图31为晶型B受压前后的XRPD叠图；
图32为晶型D受压前后的XRPD叠图；
图33为晶体中化合物(晶型B)的绝对构型；
图34为晶型B不对称单位的立体结构椭球图；
图35为单个分子的立体结构椭球图；
图36为沿a轴方向的晶胞堆积投影图。
具体实施方式
为使上述内容更清楚、明确，本发明将用以下实施例来进一步阐述本发明的技术方案。以下实施例仅用于说明本发明的具体实施方式，以使本领域的技术人员能够理解本发明，但不用于限制本发明的保护范围。本发明的具体实施方式中，未作特别说明的技术手段或方法等为本领域的常规技术手段或方法等。本发明的手性化合物可通过手性合成或常规手性柱进行拆分纯化。
除非另有说明，本发明所有温度均指摄氏度。
实施例中使用了下列缩略语：
n-BuLi：正丁基锂；
Dioxane：二氧六环；
DCM：二氯甲烷；
DMSO：二甲基亚砜；
DIEA或DIPEA：N,N-二异丙基乙胺；
TFA：三氟乙酸；
TBSCl：叔丁基二甲基氯硅烷；
DIC：N,N-二异丙基碳二亚胺；
PCC：氯铬酸吡啶盐；
TBAF：四丁基氟化铵三水合物；
THF：四氢呋喃；
MeOH：甲醇；
DMAP：4-二甲氨基吡啶；
DMF：N,N-二甲基甲酰胺；
PdCl2(dppf)：[1,1'-双(二苯基膦基)二茂铁]二氯化钯；
PE：石油醚；
Xantphos：4,5-双二苯基膦-9,9-二甲基氧杂蒽；
Pd(AcO)2：醋酸钯；
Pd2(dba)3：三(二亚苄基丙酮)二钯；
Dess-Martin reagent：戴斯-马丁试剂；
LC-MS：液相色谱-质谱联用；
1H NMR：核磁共振仪氢谱；
IC：离子色谱；
h或hrs：小时；
min：分钟。
除非另有说明，本发明所用到的检测仪器信息和检测方法参数如表1-5所示：
表1
表2
表3
表4
表5

对比实施例1
参照WO2019168744A1实施例2的合成方法，合成对比化合物D1，LC-MS：[M+H]+＝287。
实施例1：化合物M1的制备
步骤1：化合物M1-2的合成
将磷酰基乙酸三乙酯(62g)和叔丁醇钠(26g)溶于无水1,4-二氧六环(70mL)，降温至0℃，氮气保护下搅拌，升至室温搅拌0.5h。加入化合物M1-1(30g)，室温搅拌10min。然后转移至闷罐中，升温至150℃反应过夜。反应毕，冷却至室温后，反应体系加水搅拌，甲基叔丁基醚萃取三次，饱和食盐水洗涤，干燥、浓缩得黄色油状物(40g，产率84.21％)。即化合物M1-2。
步骤2：化合物M1-3的合成
将化合物M1-2(110g)溶于二氧六环(300mL)，NaOH(80g)溶于水(300mL)后倒入反应体系，升温至100℃反应过夜。反应毕，反应液冷却至室温后，将反应液用甲基叔丁基醚萃取三次，水相调节pH至1～2，甲基叔丁基醚萃取三次，饱和食盐水洗涤，干燥、浓缩得黄色油状物(90g,产率95.97％)。即化合物M1-3。
步骤3：化合物M1-4合成
将化合物M1-3(100g)、N-羟基邻苯二甲酰亚胺(121g)和DMAP(22g)溶于二氯甲烷(1000mL)，降温至0℃，缓慢加入DIC(93g)，然后室温反应2h。反应毕，反应液通过硅藻土过滤，滤液旋干得粗品。柱层析纯化得白色固体(100g,产率52.78％)，即化合物M1-4。
步骤4：化合物M1合成
将化合物M1-4(1.00g)、联硼酸频哪醇酯(2.48g)、无水氯化镁(0.46g)、一水合氢氧化锂(2.06g)和醋酸丙酮铜(0.26g)溶于甲基叔丁基醚(24mL)和DMF(4mL)的混合溶剂中，氮气保护下，室温反应10min。反应毕，将反应液经硅藻土抽滤，EA萃取，饱和食盐水洗，无水硫酸钠干燥，石油醚打浆，滤液柱层析纯化(PE:EA＝100:1),得到无色液体(0.25g,产率31.47％)，即化合物M1。
LC-MS：[M+H]+＝245.2
实施例2：(5-(6-氯-5-((1S，2S)-2-苯基环丙基)哒嗪-3-基)嘧啶-2,4(1H，3H)-二酮)(化合物(Ⅰ))的合成
步骤1：化合物Ⅰ-1的合成
50mL三口瓶中加入4-溴-3,6-二氯哒嗪(1.8g)，化合物M1(2.3g)，[1,1'-双(二苯基膦)二茂铁]二氯化钯(0.6g)，碳酸钾(1.6g)，二氧六环(20mL)，水(4mL)，N2保护下，加热至60℃反应12h。反应毕，将反应液倒入水中，乙酸乙酯萃取，饱和食盐水洗，干燥浓缩得到粗品，经柱层析纯化得到白色固体(1.4g,产率66.85％)。即化合物Ⅰ-1。
步骤6：化合物Ⅰ-2的合成
50mL三口瓶中加入化合物Ⅰ-1(1.3g)，(2,4-二甲氧基嘧啶-5-基)硼酯(1.8g)，[1,1'-双(二苯基膦)二茂铁]二氯化钯(0.2g)，碳酸钾(1g)，二氧六环(15mL)，水(3mL)，N2保护下， 加热至60℃反应2h。反应毕，将反应液倒入水中，乙酸乙酯萃取，饱和食盐水洗，干燥浓缩得到粗品，经柱层析纯化得到白色固体粗品，粗品用甲醇打浆，抽滤得到白色固体(0.6g,产率33.18％)。即化合物Ⅰ-2。
步骤7：化合物Ⅰ的合成
50mL单口瓶中加入化合物Ⅰ-2(0.6g)，1M盐酸水溶液(5mL)，THF(5mL)，升至50℃搅拌反应8h。反应毕，将反应液抽滤，滤饼用少量二氯甲烷甲醇混合溶液打浆，抽滤得到白色固体(0.4g,产率66.67％)。即化合物(Ⅰ)(纯度99.57％)。
LC-MS：[M+H]+＝341.2
1H NMR(500MHz,DMSO-d6)δ11.61(s,1H),11.59(s,1H),8.33(s,1H),8.07(s,1H),7.35-7.29(m,2H),7.28-7.25(m,2H),7.24-7.19(m,1H),2.44-2.38(m,1H),2.38-2.31(m,1H),1.74-1.68(m,1H),1.67-1.61(m,1H).
实施例3：晶型A的制备
向1L反应釜中加入100mL丙酮溶液，再加入10g实施例2中制备的化合物(I)，升温到50℃悬浮搅拌过夜，抽滤，于室温真空干燥6小时，得到白色固体粉末，经XRPD、DSC以及TGA测定，终产品为化合物(I)晶型A。
晶型A的XRPD谱图基本上如图1所示。
晶型A的mDSC谱图如图2，吸热峰峰值约为258.0℃。
晶型A的TGA谱图如图3，在150.0℃前共失重约0.2％。
表6晶型A的XRPD特征峰

实施例4：晶型B的制备
方法一：向100ml应瓶中加入50mL丙酮溶液，再加入5g实施例2中制备的化合物(Ⅰ)，升温到25℃悬浮搅拌过夜，抽滤，得到产物得到白色固体粉末，于室温真空干燥6小时，经XRPD、DSC以及TGA测定，终产品为化合物(I)晶型B。
晶型B的XRPD谱图基本上如图4所示。
晶型B的mDSC谱图如图5，吸热峰峰值约为244.9℃，放热峰峰值约为245.2℃。
晶型B的TGA谱图如图6，样品在150.0℃前基本无失重。
表7晶型B的XRPD特征峰

方法二：称取10mg化合物(I)，加入到0.2ml乙醇中，置于25℃悬浮搅拌三天，抽滤，得到产物得到白色固体粉末，于室温真空干燥3小时，经XRPD、DSC以及TGA测定，终产品为化合物(I)晶型B。
实施例5：晶型C的制备
向500ml反应釜中加入200ml四氢呋喃/水(14/1，体积比)混合溶剂，再加入实施例2中制备的10g化合物(I)，升温到50℃，搅拌溶清，降温至20℃过滤，将滤液转移至500ml反应釜中，量取100ml正庚烷，滴加到反应液中，约3小时滴加完毕。降温至0℃左右，平衡过夜，抽滤，得到产物得到白色固体粉末，于室温真空干燥过夜，经XRPD、DSC以及TGA测定，终产品为化合物(I)晶型C。
晶型C的XRPD谱图基本上如图7所示。
晶型C的DSC谱图基本如图8，放热峰峰值约为268.1℃。
晶型C的TGA谱图基本如图9，150.0℃前共失重约1.5％。
表8晶型C的XRPD特征峰

实施例6：晶型D的制备
称取500mg实施例2中制备的化合物(I)样品，加入到10ml二氯甲烷溶剂，置于50℃温度下悬浮搅拌两天，抽滤得到白色固体于室温真空干燥过夜，经XRPD、DSC以及TGA测定，终产品为化合物(I)晶型D。
晶型D的XRPD谱图基本上如图10所示。
晶型D的DSC谱图如图11，放热峰峰值约为274.5℃。
晶型D的TGA谱图如图12，150.0℃前共失重约0.5％。
表9晶型D的XRPD特征峰

实施例7：晶型F的制备
称取5g实施例2中制备的化合物(I)样品，加入到50ml甲醇溶剂，置于50℃温度下悬浮过夜，抽滤得到白色固体，室温晾干，经XRPD、DSC以及TGA测定，终产品为化合物(I)晶型F。
晶型F的XRPD谱图基本上如图13所示。
晶型F的DSC谱图如图14，吸热峰峰值约为47.6℃，放热峰峰值约为276.9℃。
晶型F的TGA谱图如图15，60.0℃之前的失重2.9％。
表10晶型F的XRPD特征峰

实施例8：晶型G的制备
称取10mg实施例2中制备的化合物(I)样品，加入到1ml二甲基亚砜/丁酮(1/1，体积比)混合溶剂中，置于50℃温度下悬浮搅拌一天，过滤，室温真空干燥过夜，得到白色固体，经XRPD、DSC以及TGA测定，终产品为化合物(I)晶型G。
晶型G的XRPD谱图基本上如图16所示。
晶型G的DSC谱图如图17，吸热峰峰值约为110.1℃，128.0℃和141.8℃，放热峰峰值约为251.4℃。
晶型G的TGA谱图如图18，130.0℃之前失重量24.7％。
表11晶型G的XRPD特征峰
实施例9：晶型H的制备
称取10mg实施例2中制备的化合物(I)样品，加入到1ml二甲基亚砜/乙酸乙酯(1/9，体积比)混合溶剂中，置于50℃温度下悬浮搅拌一天，过滤，室温真空干燥过夜，得到白色固体，经XRPD、DSC以及TGA测定，终产品为化合物(I)晶型H。
晶型H的XRPD谱图基本上如图19所示。
晶型H的DSC谱图如图20，吸热峰峰值约为95.8℃、107.2℃和117.8℃，放热峰峰值为约263.1℃。
晶型H的TGA谱图如图21，在130.0℃前失重约18.1％。
表12晶型H的XRPD特征峰

实施例10：晶型I的制备
称取10mg实施例2中制备的化合物(I)样品，加入到0.3ml二氯甲烷溶剂中，置于5℃温度下悬浮搅拌十天，过滤，室温真空干燥过夜，得到白色固体，经XRPD、DSC和TGA测定，终产品为化合物(I)晶型I。
晶型I的XRPD谱图基本上如图22所示。
晶型I的DSC谱图如图23，吸热峰峰值约为267.4℃。
晶型I的TGA谱图如图24，在约140℃前共失重约0.8％。
表13晶型I的XRPD特征峰
实施例10：晶型J的制备
称取5mg实施例2中制备的化合物(I)的晶型I样品，使用TGA在氮气氛围下以10℃/min的升温速率加热至140.0℃，并维持20min后，抽滤干燥得到白色固体，经XRPD测定，终产品为化合物(I)晶型J。
经X-射线粉末衍射检测，晶型J的XRPD谱图基本上如图25所示。
表14晶型J的XRPD特征峰

实施例11：晶型K的制备
称取10mg实施例2中制备的化合物(I)样品，加入到0.3ml甲基异丁基酮溶剂中，置于5℃温度下悬浮搅拌十天，过滤，室温真空干燥过夜，得到白色固体，经XRPD测定，终产品为化合物(I)晶型K。
经X-射线粉末衍射检测，晶型K的XRPD谱图基本上如图26所示。
表15晶型K的XRPD特征峰
实施例12：硫酸盐晶型L的制备
称取10mg实施例2中制备的化合物(I)样品，加入到10ml丙酮溶剂中，缓慢滴加25μl的硫酸，置于25℃温度下搅拌2小时，过滤，室温真空干燥过夜，得到白色固体，经XRPD、TGA、DSC，终产品为化合物(I)的硫酸盐晶型L，摩尔比为1:1。
硫酸盐晶型L的XRPD谱图基本上如图27所示。
硫酸盐晶型L的DSC谱图如图28，吸热峰峰值约为66.8℃，放热峰峰值约为208.8℃。
硫酸盐晶型L的TGA谱图如图29，在约100.0℃前共失重约3.9％。
表16硫酸盐晶型L的XRPD特征峰
实施例13：稳定性的测定
测定本发明的晶型的稳定性。将化合物(I)的晶型A和晶型B分别置于高温60℃、高湿92.5％RH、40℃/75％RH和25℃/60％RH条件下进行稳定性测试，于第0天、第7天、第14天和第30天取样，所取样品测定有关物质，并与初始数据比较。比较结果发现，化合物(I)晶型A和晶型B均具有良好的化学稳定性。
表17晶型A的稳定性数据

表18晶型B的稳定性数据
实施例15：动态水分吸附(DVS)的测定
本发明的动态吸附仪检测设备和方法如表19所示，动态水分吸附测定结果，其中DVS结果显示：晶型B无引湿性；晶型A、晶型C和晶型D均略有引湿性，具体数据如表20所示。同时，经X射线粉末衍射测试，DVS测试后的晶型A，B，C，D均未发生改变。
表19动态水分吸附仪检测设备和方法数据

表20动态水分吸附测定结果
实施例16压力敏感性测试
对晶型A、晶型B和晶型D进行压力敏感性测试。将实施例3中制备的晶型A、实施例4中制备的晶型B和实施例6中制备的晶型D分别在150kg和230kg的压力条件下受压30秒，测试受压后样品的晶型变化。XRPD结果显示，晶型B样品在150kg和230kg压力条件下受压前后结晶度和晶型未发生明显变化。具体XRPD叠图，详见图30至图32。实施例17化合物(Ⅰ)晶型B的单晶结构确认与解析
单晶衍射试验：照《中国药典》2020年版四部通则0451第一法测定，测试条件：CuKα辐射，扫描。单晶衍射实验收集总衍射点数为9785个，独立衍射点数4800个，可观察点数(|F|2≥2σ|F|2)为4631个。
结构解析：采用直接法(Shelxs97)解析晶体结构，晶体属三斜晶系，空间群为P1，晶胞参数：α＝77.38(3)°，β＝85.51(3)°，γ＝87.18(3)°；晶胞体积晶胞内不对称单位数Z＝1。使用最小二乘法修正结构参数和判别原子种类，使用几何计算法得到全部氢原子位置，最终可靠因子R1＝0.0343，wR2＝0.0930，S＝1.029。最终确定不对称单位的化学计量式为2(C17H13N4O2Cl)，计算单个分子的分子量为340.76，计算晶体密度为1.438g/cm3。
结果表明：化合物(Ⅰ)晶态下分子排列属于第一类空间群，样品应具有旋光活性，Flack系数0.053(12)，可确定晶体中化合物的绝对构型如图33所示。晶态下分子间以氢键和范德华力维系其在空间的稳定排列。不对称单位的立体结构椭球图如图34所示，单个分子的立体结构椭球图如图35所示，沿a轴方向的晶胞堆积投影图如图36所示。
药理实验
药理实施例1：细胞水平的酶学活性检测
将Calu-6细胞消化，使用TM buffer(25mM Tris,5mM MgCl2,pH 7.5)重悬细胞，按25000细胞、100μL/孔铺96孔板。TM buffer配制梯度浓度的化合物溶液，分别向各孔细胞中加入50μL各浓度的待测化合物DMSO溶液，化合物终浓度为20000、6666.7、2222.2、740.7、246.9、82.3、27.4、9.1、3.0、1.0、0.3、0nM(DMSO终浓度均为0.625％)。37℃恒温水平摇床预孵育30min，各孔中加入50μL 800μM AMP溶液，37℃恒温水平摇床继续孵育120min后，将96孔板离心，每孔转移50μL上清液至新的96孔板中，每孔中加入50μL 130μM ATP溶液和100μL Cell-titer Glo工作液，震荡混匀后室温孵育10min，多功能酶标仪读取Luminescence发光值，将发光值读数转换为抑制百分数：
抑制百分数＝(1-读数/最大值)*100。
“最大值”为DMSO对照。
用GraphPad Prism软件进行曲线拟合并得到IC50值。
实施例化合物在Calu-6细胞水平的酶学IC50数据参见表21。本发明化合物具有良好活性。
表21
药理实施例2：药代动力学评价
以小鼠为受试动物，应用LC/MS/MS法测定小鼠灌胃给予实施例化合物后不同时刻血浆中的药物浓度。研究本发明化合物在小鼠体内的药代动力学行为，评价其药动学特征。
实验方法：使用从维通利华实验动物有限公司购入的健康Balb/C雌性小鼠(20g左右)进行小鼠单次PK研究(PO 10mg/kg)。在给药前1h左右，称取一定量药物，加入5％DMSO、95％的羟丙基倍他环糊精(HP-β-CD)溶液配置成无色澄明溶液。HP-β-CD溶液为HP-β-CD粉末加入0.9％生理盐水中配置而成的20％HP-β-CD水溶液。灌胃给药是以10mL/kg的给药体积进行给药，通过小鼠眼眶静脉丛采血，采血时间点如下：给药前及给药后0.25、0.5、1.0、2.0、4.0、7.0、24.0小时，每个时间点采取100uL的全血至K2EDTA抗凝管，将采集的全血样品以4000rpm离心10分钟，分离得到血浆并将其放入-80℃冰箱保存。
将上述血浆样品，加入含有内标的纯乙腈溶液蛋白沉淀前处理后，10000rpm离心10分钟，取上清液，并与水1：1混合，取10μL至LC-MS/MS检测，化合物在血浆样品检测的线性范围是1-1000ng/mL，得到的数据结果如下：
实验结果：化合物的药代动力学参数如下表22。本发明化合物的药代吸收良好，具有明显的药代动力学优势。
表22
药理实施例3小鼠细胞表面CD73酶活性评价
细胞来源：中国科学院细胞库，货号SCSP-5056；
细胞培养：复苏细胞，置于37℃、5％CO2培养箱中培养，观察细胞生长状态良好。至少传代两代，培养至细胞融合度为80％-90％，培养基及细胞名称见表23。
表23
细胞铺板：
a)吸弃4T1细胞培养基，PBS清洗细胞一次，加入0.25％Trypsin-EDTA消化并收集4T1细胞，加入相应的培养基终止消化并重悬，利用细胞计数仪进行计数，确保细胞活力大于90％；
b)使用酶学缓冲液(25mM Tris，5mM MgCl2，pH7.5)对重悬液进行稀释，配制成对应密度的细胞悬液，4T1细胞密度均为2.5×105cells/mL；
c)按100μL/孔的体积，将4T1细胞悬液种至96孔细胞培养板中，每孔细胞数量为2.5×104个；
化合物配置：分别称取晶型B，对比化合物D1，折算含量，加入对应体积DMSO，配置储备液，涡旋混匀至澄清。
待测化合物酶学反应步骤：
a)配置待测样品稀释液：用DMSO对待测化合物晶型B、对比化合物D1的20mM DMSO储存液进行3倍梯度稀释，共11个浓度点，先用DMSO对每个浓度的样品进行 6.25倍稀释，再用酶学缓冲液对每个浓度的样品进行40倍稀释，得到4倍于终浓度的样品稀释液。样品稀释液中DMSO浓度为2.5％，检测体系中DMSO终浓度为0.625％。
b)根据检测布局向每孔中加入50μL对应的待测样品稀释液，Negative control组加入50μL含2.5％DMSO的酶学缓冲液，代替待测样品稀释液，将细胞培养板放置在37℃恒温水平摇床孵育30分钟，反应液体积为150μL。
c)用酶学缓冲液配制浓度为1600μM的AMP稀释液，根据检测布局向4T1细胞(高表达小鼠CD73)培养板中每孔加入50μL的AMP稀释液(终浓度为400μM)，37℃恒温水平摇床继续孵育120分钟，反应液总体积为200μL。AMP底物浓度和孵育时间根据4T1细胞CD73表达水平进行了滴定确认。
d)孵育结束后，将细胞培养板从37℃恒温水平摇床取出，1000rpm离心5分钟。每孔转移50μL上清液至96孔细胞培养板。
e)用酶学缓冲液配制浓度为130μM的ATP稀释液，根据检测布局向含有50μL上清液的96孔细胞培养板中每孔加入50μL的ATP稀释液和100μL CellTiter-Glo工作液，震荡混匀后避光室温孵育10分钟。
f)利用多功能酶标仪Envision读取化学发光信号值(Luminescence)。
数据分析：
g)利用GraphPad Prism 8 software计算IC50(半数抑制浓度)，利用以下非线性拟合公式来得到化合物的IC50。
Y＝Bottom+(Top-Bottom)/(1+10^((LogIC50-X)×HillSlope))
X：化合物浓度Log值
Y：抑制率(％inhibition)
抑制率(％inhibition)＝100％-(化合物孔读值-Positive control)/(Negative control-Positive control)×100％
Positive control：20μM对比化合物D1
Negative control：0.625％DMSO
h)IC50的值是指相对半数抑制浓度，即在拟合曲线中最高和最低抑制率之间一半抑制率所对应的化合物浓度，结果见表29。
药理实施例4人细胞表面CD73酶活性评价
细胞来源：中国科学院细胞库，货号GNHa 7；
细胞培养：复苏细胞，置于37℃、5％CO2培养箱中培养，观察细胞生长状态良好。至少传代两代，培养至细胞融合度为80％-90％，细胞名称及培养基见表24。
表24
CHO-K1细胞转染：
a)利用pcDNA3.1载体插入人编码CD73蛋白的NT5E基因，得到过表达人CD73的质粒。
b)将CHO-K1细胞接种在细胞培养瓶中。待细胞密度达到70％-80％，利用Lipo8000脂质体转染试剂向CHO-K1细胞转染人CD73质粒。质粒的转染体系为：15μg质粒+24μLLipo8000+750μL无血清MEM，将此转染体系加入到含新鲜培养基的细胞培养瓶中，轻柔混匀后将细胞放入细胞孵育箱继续培养。转染后次日更换新鲜培养基，继续培养72小时，得到CHO-K1-hCD73细胞(过表达人CD73)进行后续实验。
细胞铺板：
a)吸弃CHO-K1-hCD73细胞培养基，PBS清洗细胞一次，加入0.25％Trypsin-EDTA消化并收集细胞，加入培养基终止消化并重悬，并利用细胞计数仪进行计数，确保细胞活力大于90％。
b)使用酶学缓冲液(25mM Tris，5mM MgCl2，pH7.5)对重悬液进行稀释，配制成细胞密度为2.5×105cells/mL的细胞悬液。
c)按100μL/well的体积，将CHO-K1-hCD73细胞悬液种至96孔细胞培养板中，每孔细胞数量为2.5×104个。
化合物配置：分别称取晶型B，对比化合物D1，折算含量，加入对应体积DMSO，配置储备液，涡旋混匀至澄清。
待测化合物酶学反应步骤：
a)配置待测样品稀释液：用DMSO对待测化合物晶型B、对比化合物D1的20mM DMSO储存液进行3倍梯度稀释，共11个浓度点，先用DMSO对每个浓度的样品进行6.25倍稀释，再用酶学缓冲液对每个浓度的样品进行40倍稀释，得到4倍于终浓度的样品稀释液。样品稀释液中DMSO浓度为2.5％，检测体系中DMSO终浓度为0.625％。
b)根据检测布局向上述100μL的细胞悬液中，每孔中加入50μL对应的待测样品稀释液，Negative control组加入50μL含2.5％DMSO的酶学缓冲液，代替待测样品稀释液。将CHO-K1-hCD73细胞培养板放置在37℃恒温水平摇床孵育30分钟。
c)用酶学缓冲液配制浓度为800μM的AMP稀释液，根据检测布局向上述150μL CHO-K1-hCD73细胞反应液中每孔加入50μL的AMP稀释液(终浓度为200μM)，37℃恒温水平摇床继续孵育60分钟。AMP底物浓度和孵育时间已根据CHO-K1-hCD73细胞CD73表达水平进行了滴定确认。
d)孵育结束后，将CHO-K1-hCD73细胞培养板从37℃恒温水平摇床取出，1000rpm离心5分钟。每孔转移50μL上清液至新的96孔细胞培养板。
e)用酶学缓冲液配制浓度为130μM的ATP稀释液，根据检测布局向含有50μL上清液的96孔细胞培养板中，每孔加入50μL的ATP稀释液和100μL CellTiter-Glo工作液，震荡混匀后避光室温孵育10分钟。
f)利用多功能酶标仪EnVision读取化学发光信号值。
数据分析：
a)利用GraphPad Prism 8 software拟合量-效关系曲线，利用以下非线性拟合公式来得到化合物的IC50。
Y＝Bottom+(Top-Bottom)/(1+10^((LogIC50-X)×HillSlope))
X：化合物浓度Log值
Y：抑制率(％inhibition)
抑制率(％inhibition)＝100％-(化合物孔读值-Positive control)/(Negative control-Positive control)×100％
Positive control:20μM对比化合物D1
Negative control：0.625％DMSO
b)IC50的值是指相对半数抑制浓度，即在拟合曲线中最高和最低抑制率之间一半抑制率所对应的化合物浓度。结果见表29。
药理实施例5：MC38.WT荷瘤小鼠血浆CD73酶活性评价
血浆来源：江苏集萃药康生物科技股份有限公司；
CD73酶反应缓冲液(1×)：
表26

注：0.01％BSA，10μM SBI-425现用现配。
血浆配方见表27：
表27
底物混合物配方见表28：
表28
血浆样品准备：
分别取1.5μL受试物血浆样品置于Nanodrop检测基座上，检测受试物血浆样品的蛋白浓度，后使用CD73酶反应缓冲液将血浆样品稀释到0.5mg/mL。
具体步骤：
1)转移40nL对比化合物D1到384反应板中，1000rpm离心1分钟。
2)转移2μL AMP到384反应板中，1000rpm离心1分钟。
3)用CD73酶反应缓冲液将化合物晶型B及对比化合物D1进行稀释，将2μL血浆转移到384孔中，1000rpm离心1分钟，25℃孵育120分钟。
4)转移4μL AMP-Glo ReagentⅠ到384反应板中，1000rpm离心1分钟，25℃孵育40分钟。
5)转移8μL AMP-Glo ReagentⅡ和Kinase Glo混合液到384反应板中，1000rpm离心1分钟，25℃孵育40分钟。
6)用多功能酶标仪读取Luminescence信号。
数据处理方法：
1)抑制率计算：
抑制率(％inhibition)＝100％-(化合物孔读值-Positive control)/(Negative control-Positive  control)×100％
Positive control：10μM对比化合物D1
Negative control：1％DMSO
2)利用GraphPad Prism software非线性拟合公式计算对比化合物D1的IC50：
Y＝Bottom+(Top-Bottom)/(1+10^((LogIC50-X)×HillSlope))
X：化合物浓度Log值
Y：抑制率(％inhibition)
3)异常数据剔除遵循t检验标准，首先将实验数据按大小排列x(1)≤x(2)≤x(3),……≤x(n)，对最小数据和最大数据分别进行检验，如果或则x(1)或x(n)是异常数据，应予剔除，式中及σ*分别为不包括x(1)或x(n)的n-1个数据的均值和标准差。结果见表29。
表29
可以看出，本发明中的晶型对肿瘤细胞CD73酶活和可溶性CD73酶活均具有高效的抑制活性。
虽然本发明已通过其实施方式进行了全面的描述，但是值得注意的是，各种变化和修改对于本领域技术人员都是显而易见的。这样的变化和修改都应该包括在本发明所附权利要求的范围内。

Claims (56)

  1. 5-(6-氯-5-((1S，2S)-2-苯基环丙基)哒嗪-3-基)嘧啶-2,4(1H，3H)-二酮游离碱的晶型形式。
  2. 5-(6-氯-5-((1S，2S)-2-苯基环丙基)哒嗪-3-基)嘧啶-2,4(1H，3H)-二酮的晶型A，其特征在于，X射线粉末衍射谱图中在2θ为4.521°、7.268°、11.930°、15.837°和16.946°处具有特征峰，2θ值误差范围为±0.2°。
  3. 根据权利要求2的晶型A，其特征在于，X射线粉末衍射谱图中在2θ为4.521°、7.268°、11.442°、11.930°、15.837°、16.946°和22.717°处具有特征峰，2θ值误差范围为±0.2°。
  4. 根据权利要求2或3的晶型A，其特征在于，X射线粉末衍射谱图中在2θ为4.521°、7.268°、11.442°、11.930°、15.141°、15.518°、15.837°、16.946°、22.717°、23.867°和25.581°处具有特征峰，2θ值误差范围为±0.2°。
  5. 根据权利要求2-4任一项所述的晶型A，其特征在于，X射线粉末衍射谱图具有图1所示的特征峰。
  6. 根据权利要求2-5中任一项所述的晶型A，所述晶型A的mDSC曲线在258.0℃±3℃处有一个吸热峰，优选地，其mDSC曲线图谱如2所示。
  7. 5-(6-氯-5-((1S，2S)-2-苯基环丙基)哒嗪-3-基)嘧啶-2,4(1H，3H)-二酮的晶型B，其特征在于，X射线粉末衍射谱图中在2θ为4.789°、15.673°和24.161°处具有特征峰，2θ值误差范围为±0.2°。
  8. 根据权利要求7的晶型B，其特征在于，X射线粉末衍射谱图中在2θ为4.789°、9.598°、15.673°和24.161°处具有特征峰，2θ值误差范围为±0.2°。
  9. 根据权利要求7或8的晶型B，其特征在于，X射线粉末衍射谱图中在2θ为4.789°、9.598°、14.424°、15.673°和24.161°处具有特征峰，2θ值误差范围为±0.2°。
  10. 根据权利要求7-9中任一项所述的晶型B，其特征在于，X射线粉末衍射谱图中在2θ为4.789°、9.598°、10.076°、14.424°、15.275°、15.673°、19.262°、24.161°处具有特征峰，2θ值误差范围为±0.2°。
  11. 根据权利要求7-10中任一项所述的晶型B，其特征在于，X射线粉末衍射谱图中在2θ为4.789°、9.598°、10.076°、14.424°、15.275°、15.673°、19.262°、19.714°、19.989°、20.229°、24.161°和27.193°处具有特征峰，2θ值误差范围为±0.2°。
  12. 根据权利要求7-11中任一项所述的晶型B，其特征在于，X射线粉末衍射谱图具有图4所示的特征峰。
  13. 根据权利要求7-12中任一项所述的晶型B，所述晶型B的mDSC曲线在228.7.5℃±3℃和244.9℃±3℃处有一个吸热峰，在245.2℃±3℃处有一个放热峰，优选地，其mDSC曲线图谱如5所示。
  14. 5-(6-氯-5-((1S，2S)-2-苯基环丙基)哒嗪-3-基)嘧啶-2,4(1H，3H)-二酮的晶型C，其特征在于，X射线粉末衍射谱图中在2θ为3.854°、5.250°、7.126°、14.870°、16.357°、19.629°、21.613°、和21.982°处具有特征峰，2θ值误差范围为±0.2°。
  15. 根据权利要求14的晶型C，其特征在于，X射线粉末衍射谱图中在2θ为3.854°、5.250°、7.126°、14.870°、15.925°、16.357°、18.581°、19.629°、21.613°和21.982°处具有特征峰，2θ值误差范围为±0.2°。
  16. 根据权利要求14或15的晶型C，其特征在于，X射线粉末衍射谱图中在2θ为3.854°、5.250°、7.126°、14.870°、15.925°、16.357°、18.581°、19.629°、21.613°、21.982°、23.831°、25.578°、30.069°、33.684°和36.482°处具有特征峰，2θ值误差范围为±0.2°。
  17. 根据权利要求14-16任一项所述的晶型C，其特征在于，X射线粉末衍射谱图具有图7所示的特征峰。
  18. 根据权利要求14-17中任一项所述的晶型C，所述晶型C的DSC曲线在268.1℃±3℃处有一个放热峰，优选地，其DSC曲线图谱如8所示。
  19. 5-(6-氯-5-((1S，2S)-2-苯基环丙基)哒嗪-3-基)嘧啶-2,4(1H，3H)-二酮的晶型D，其特征在于，X射线粉末衍射谱图中在2θ为4.661°、12.132°、15.653°、23.500°、26.514°和27.356°处具有特征峰，2θ值误差范围为±0.2°。
  20. 根据权利要求19的晶型D，其特征在于，X射线粉末衍射谱图中在2θ为4.661°、12.132°、14.033°、15.653°、17.891°、19.937°、23.500°、24.942°、26.514°和27.356°处具有特征峰，2θ值误差范围为±0.2°。
  21. 据权利要求19或20所述的晶型D，其特征在于，其X射线粉末衍射谱图具有图10所示的特征峰。
  22. 根据权利要求19-21中任一项所述的晶型D，所述晶型D的DSC曲线在274.5℃±3℃处有一个放热峰，优选地，其DSC曲线图谱如11所示。
  23. 5-(6-氯-5-((1S，2S)-2-苯基环丙基)哒嗪-3-基)嘧啶-2,4(1H，3H)-二酮的晶型F，其特征在于，X射线粉末衍射谱图中在2θ为4.525°、6.885°、11.848°、14.337°、16.594°和24.492°处具有特征峰，2θ值误差范围为±0.2°。
  24. 根据权利要求23的晶型F，其特征在于，X射线粉末衍射谱图中在2θ为4.525°、6.885°、11.021°、11.848°、14.337°、16.594°、22.965°和24.492°处具有特征峰，2θ值误差范围为±0.2°。
  25. 根据权利要求23或24的晶型F，其特征在于，X射线粉末衍射谱图中在2θ为4.525°、5.471°、6.885°、9.492°、11.021°、11.848°、13.311°、14.337°、14.893°、16.594°、17.182°、18.276°、22.965°、24.492°和25.446°处具有特征峰，2θ值误差范围为±0.2°。
  26. 根据权利要求23-25的晶型F，其特征在于，X射线粉末衍射谱图具有图13所示的特征峰。
  27. 根据权利要求23-26中任一项所述的晶型F，所述晶型F的DSC曲线在47.6℃±3℃处有一个吸热峰，在276.9℃±3℃处有一个放热峰，优选地，其DSC曲线图谱如14所示。
  28. 5-(6-氯-5-((1S，2S)-2-苯基环丙基)哒嗪-3-基)嘧啶-2,4(1H，3H)-二酮的晶型G，其特征在于，X射线粉末衍射谱图中在2θ为5.986°、6.956°、14.011°、17.552°、19.157°和24.343°处具有特征峰，2θ值误差范围为±0.2°。
  29. 根据权利要求28的晶型G，其特征在于，X射线粉末衍射谱图中在2θ为5.986°、6.956°、14.011°、17.552°、19.157°、22.300°、23.443°和24.343°处具有特征峰，2θ值误差范围为±0.2°。
  30. 根据权利要求28或29的晶型G，其特征在于，X射线粉末衍射谱图中在2θ为5.986°、6.956°、14.011°、14.354°、17.552°、18.195°、19.157°、19.509°、19.922°、22.300°、23.443°、24.343°、25.928°、29.391°和30.476°处具有特征峰，2θ值误差范围为±0.2°。
  31. 根据权利要求28-30的晶型G，其特征在于，X射线粉末衍射谱图具有图16所示的特征峰。
  32. 根据权利要求28-31中任一项所述的晶型G，所述晶型G的DSC曲线在110.1℃±3℃，128.0℃±3℃和141.8℃±3℃处有吸热峰，在251.4℃±3℃处有一个放热峰，优选地，其DSC曲线图谱如17所示。
  33. 5-(6-氯-5-((1S，2S)-2-苯基环丙基)哒嗪-3-基)嘧啶-2,4(1H，3H)-二酮的晶型H，其特征在于，X射线粉末衍射谱图中在2θ为11.838°、16.771°、21.451°和22.524°处具有特征峰，2θ值误差范围为±0.2°。
  34. 根据权利要求33的晶型H，其特征在于，X射线粉末衍射谱图中在2θ为11.838°、16.771°、17.251°、21.451°、22.524°、23.494°和26.982°处具有特征峰，2θ值误差范围为±0.2°。
  35. 根据权利要求33或34的晶型H，其特征在于，X射线粉末衍射谱图中在2θ为9.087°、9.518°、10.650°、11.838°、12.105°、16.771°、17.251°、19.655°、19.831°、20.328°、21.451°、22.524°、23.494°、24.783°、26.982°和27.507°处具有特征峰，2θ值误差范围为±0.2°。
  36. 根据权利要求33-35的晶型H，其特征在于，X射线粉末衍射谱图具有图19所示的特征峰。
  37. 根据权利要求33-36中任一项所述的晶型H，所述晶型H的DSC曲线在95.8℃±3℃，107.2℃±3℃和117.8℃±3℃处有吸热峰，在263.1℃±3℃处有一个放热峰，优选地，其DSC曲线图谱如20所示。
  38. 5-(6-氯-5-((1S，2S)-2-苯基环丙基)哒嗪-3-基)嘧啶-2,4(1H，3H)-二酮的晶型I，其特征在于，X射线粉末衍射谱图中在2θ为3.999°、6.693°、13.476°和20.308°处具有特征峰，2θ值误差范围为±0.2°。
  39. 根据权利要求38的晶型I，其特征在于，X射线粉末衍射谱图中在2θ为3.999°、5.042°、6.693°、13.476°、20.308°、26.507°和27.212°处具有特征峰，2θ值误差范围为±0.2°。
  40. 根据权利要求38或39的晶型I，其特征在于，X射线粉末衍射谱图中在2θ为3.999°、5.042°、6.693°、13.476°、16.656°、20.308°、22.481°、23.476°、26.507°、27.212°、27.852°、28.944°和34.216°处具有特征峰，2θ值误差范围为±0.2°。
  41. 据权利要求38-40的晶型I，其特征在于，X射线粉末衍射谱图具有图22所示的特征峰。
  42. 根据权利要求38-41中任一项所述的晶型I，所述晶型I的DSC曲线在267.4℃±3℃处有吸热峰，优选地，其DSC曲线图谱如23所示。
  43. 5-(6-氯-5-((1S，2S)-2-苯基环丙基)哒嗪-3-基)嘧啶-2,4(1H，3H)-二酮的晶型J，其特征在于，X射线粉末衍射谱图中在2θ为4.543°、6.712°、13.492°和20.318°处具有特征峰，2θ值误差范围为±0.2°。
  44. 根据权利要求43的晶型J，其特征在于，X射线粉末衍射谱图中在2θ为4.543°、6.712°、13.492°、20.318°、23.461°、26.520°、27.226°和34.227°处具有特征峰，2θ值误差范围为±0.2°。
  45. 根据权利要求44或43的晶型J，其特征在于，X射线粉末衍射谱图具有图25所示的特征峰。
  46. 5-(6-氯-5-((1S，2S)-2-苯基环丙基)哒嗪-3-基)嘧啶-2,4(1H，3H)-二酮的晶型K，其特征在于，X射线粉末衍射谱图中在2θ为4.119°、4.608°、12.526°和14.347°处具有特征峰，2θ值误差范围为±0.2°。
  47. 根据权利要求46的晶型K，其特征在于，X射线粉末衍射谱图中在2θ为4.119°、4.608°、12.526°、13.654°、13.996°、14.347°、23.478°和25.156°处具有特征峰，2θ值误差范围为±0.2°。
  48. 根据权利要求46-47所述的晶型K，其特征在于，X射线粉末衍射谱图具有图26所示的特征峰。
  49. 5-(6-氯-5-((1S，2S)-2-苯基环丙基)哒嗪-3-基)嘧啶-2,4(1H，3H)-二酮的硫酸盐的晶型形式。
  50. 5-(6-氯-5-((1S，2S)-2-苯基环丙基)哒嗪-3-基)嘧啶-2,4(1H，3H)-二酮的硫酸盐的硫酸盐晶型L，其特征在于，X射线粉末衍射谱图中在2θ为4.387、8.711和17.402处具有特征峰，2θ值误差范围为±0.2°。
  51. 根据权利要求50的硫酸盐晶型L，其特征在于，X射线粉末衍射谱图中在2θ为4.387、8.711、13.049、16.448、17.402、19.606、27.029和35.138处具有特征峰，2θ值误差范围为±0.2°。
  52. 根据权利要求50或51的硫酸盐晶型L，其特征在于，X射线粉末衍射谱图具有图27所示的特征峰。
  53. 根据权利要求50-52中任一项所述的硫酸盐晶型L，所述硫酸盐晶型L的DSC曲线在66.8℃±3℃有一个吸热峰，在208.8℃±3℃处有一个放热峰，优选地，其DSC曲线图谱如28所示。
  54. 结晶组合物，其包含根据权利要求1-53中任一项所述的式(I)化合物或其晶型，其中所述权利要求1-53中任一项所述的式(I)化合物或其晶型占所述结晶组合物重量的50％以上，较好是75％以上，更好是90％以上，最好是95％以上。
  55. 药物组合物，其包含根据权利要求1-53中任一项所述的式(I)化合物或其晶型或权利要求54所述的结晶组合物，以及任选的药学上可接受的辅料。
  56. 权利要求1-53中任一项所述的式(I)化合物或其晶型、权利要求45所述的结晶组合物或权利要求55所述的药物组合物在预防或治疗由CD73介导的疾病中的用途，或者在制备用于预防或治疗由CD73介导的疾病的药物中的用途；优选地，所述由CD73介导的疾病为肿瘤；更优选地，所述肿瘤选自乳腺癌、多发性骨髓瘤、膀胱癌、子宫内膜癌、胃癌、宫颈癌、横纹肌肉瘤、非小细胞肺癌、小细胞肺癌、多形性肺癌、卵巢癌、食管癌、黑色素瘤、结肠直肠癌、肝细胞瘤、头颈部肿瘤、肝胆管细胞癌、骨髓增生异常综合征、恶性胶质瘤、前列腺癌、甲状腺癌、徐旺氏细胞瘤、肺鳞状细胞癌、苔藓样角化病、滑膜肉瘤、皮肤癌、胰腺癌、睾丸癌或脂肪肉瘤。
PCT/CN2023/079559 2022-03-07 2023-03-03 一种哒嗪类衍生物的晶型、制备方法及其应用 WO2023169327A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210225734 2022-03-07
CN202210225734.4 2022-03-07

Publications (1)

Publication Number Publication Date
WO2023169327A1 true WO2023169327A1 (zh) 2023-09-14

Family

ID=87937243

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/079559 WO2023169327A1 (zh) 2022-03-07 2023-03-03 一种哒嗪类衍生物的晶型、制备方法及其应用

Country Status (1)

Country Link
WO (1) WO2023169327A1 (zh)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111819173A (zh) * 2018-03-01 2020-10-23 伊莱利利公司 Cd73抑制剂
WO2021041319A1 (en) * 2019-08-29 2021-03-04 Eli Lilly And Company Crystalline forms of a cd73 inhibitor
CN114057693A (zh) * 2020-08-03 2022-02-18 贝达药业股份有限公司 Cd73抑制剂及其在医药上的应用
WO2022052886A1 (zh) * 2020-09-08 2022-03-17 贝达药业股份有限公司 Cd73抑制剂及其在医药上的应用
WO2022121914A1 (zh) * 2020-12-10 2022-06-16 上海翰森生物医药科技有限公司 氧代氮环类衍生物调节剂、其制备方法和应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111819173A (zh) * 2018-03-01 2020-10-23 伊莱利利公司 Cd73抑制剂
WO2021041319A1 (en) * 2019-08-29 2021-03-04 Eli Lilly And Company Crystalline forms of a cd73 inhibitor
CN114057693A (zh) * 2020-08-03 2022-02-18 贝达药业股份有限公司 Cd73抑制剂及其在医药上的应用
WO2022052886A1 (zh) * 2020-09-08 2022-03-17 贝达药业股份有限公司 Cd73抑制剂及其在医药上的应用
WO2022121914A1 (zh) * 2020-12-10 2022-06-16 上海翰森生物医药科技有限公司 氧代氮环类衍生物调节剂、其制备方法和应用

Similar Documents

Publication Publication Date Title
KR100816945B1 (ko) 선택적인 사이클린 의존성 키나제 4 억제제로서의이세싸이오네이트 염
CN104725362A (zh) 吡唑基喹喔啉激酶抑制剂
CN107922348A (zh) 双环杂环酰胺衍生物
WO2018045993A1 (zh) 一种取代的2-氢-吡唑衍生物的晶型、盐型及其制备方法
CN103582638A (zh) 杂芳基并嘧啶类衍生物、其制备方法和用途
CN112961120B (zh) 一种萘基脲类化合物、其制备方法及应用
WO2020238785A1 (zh) 包括甲基和三氟甲基的双取代磺酰胺类选择性bcl-2抑制剂
Li et al. Discovery of thieno [2, 3-d] pyrimidine-based KRAS G12D inhibitors as potential anticancer agents via combinatorial virtual screening
TWI786303B (zh) 抑制ｃｄｋ4/6活性化合物的晶型及其應用
CN111217741A (zh) 氟取代单咔唑类衍生物、其制备方法及应用
WO2017144025A1 (zh) 作为EGFR抑制剂的嘧啶并[4,5-d][1,3]噁嗪-2-酮衍生物及其应用
WO2023169327A1 (zh) 一种哒嗪类衍生物的晶型、制备方法及其应用
CN108558865B (zh) 一种以吡啶并[2,3-d]嘧啶结构为母核的衍生物及其制备方法和应用
CN110467637B (zh) 一种含有氧化膦类取代苯胺的双氨基氯代嘧啶类化合物、制备方法及其应用
WO2022068860A1 (zh) 一种吡咯并杂环类衍生物的晶型及其制备方法
KR102374933B1 (ko) c-Met 억제제의 결정형과 이의 염 형태 및 제조 방법
CN114685532A (zh) 大环类化合物及其医药用途
CN114874234A (zh) 作为kras g12c抑制剂的三环类化合物及其应用
WO2023093812A1 (zh) 三氮唑酮类化合物的晶型及其应用
WO2018220252A1 (es) Derivados de piridoquinazolina eficaces como inhibidores de proteína quinasa
WO2023125947A1 (zh) 四氢异喹啉类化合物的可药用盐、晶型及其用途
EP3954693A1 (en) Crystal form of egfr inhibitor and preparation method therefor
WO2023041061A1 (zh) 一种稠合二环类衍生物的可药用盐、晶型及其制备方法
WO2022127904A1 (zh) 一种吲唑类衍生物的药学上可接受的盐、结晶形式及其制备方法
WO2021164789A1 (zh) 一种吡唑并嘧啶类化合物的晶型及其应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23765905

Country of ref document: EP

Kind code of ref document: A1